
==== Front
Biol Res
Biol Res
Biological Research
0716-9760
0717-6287
BioMed Central London

39227995
542
10.1186/s40659-024-00542-w
Review
Hormonal influence: unraveling the impact of sex hormones on vascular smooth muscle cells
Jia Keran 1
Luo Xin 12
http://orcid.org/0000-0002-7146-1360
Yi Jingyan jingyany@swmu.edu.cn

1
Zhang Chunxiang zhangchx999@163.com

3
1 grid.410578.f 0000 0001 1114 4286 Department of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Southwest Medical University, Luzhou, Sichuan 646000 China
2 https://ror.org/00g2rqs52 grid.410578.f 0000 0001 1114 4286 Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000 China
3 grid.410578.f 0000 0001 1114 4286 Department of Cardiology, The Affiliated Hospital, Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Southwest Medical University, Luzhou, Sichuan 646000 China
4 9 2024
4 9 2024
2024
57 6130 4 2024
26 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Sex hormones play a pivotal role as endocrine hormones that exert profound effects on the biological characteristics and vascular function of vascular smooth muscle cells (VSMCs). By modulating intracellular signaling pathways, activating nuclear receptors, and regulating gene expression, sex hormones intricately influence the morphology, function, and physiological state of VSMCs, thereby impacting the biological properties of vascular contraction, relaxation, and growth. Increasing evidence suggests that abnormal phenotypic changes in VSMCs contribute to the initiation of vascular diseases, including atherosclerosis. Therefore, understanding the factors governing phenotypic alterations in VSMCs and elucidating the underlying mechanisms can provide crucial insights for refining interventions targeted at vascular diseases. Additionally, the varying levels of different types of sex hormones in the human body, influenced by sex and age, may also affect the phenotypic conversion of VSMCs. This review aims to explore the influence of sex hormones on the phenotypic switching of VSMCs and the development of associated vascular diseases in the human body.

Graphical Abstract

Keywords

Sex hormones
Vascular smooth muscle cells
Phenotypic switching
Diseases
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China U23A20398, 82030007 82301845 Yi Jingyan Zhang Chunxiang http://dx.doi.org/10.13039/501100002858 China Postdoctoral Science Foundation 2023M732929 Yi Jingyan issue-copyright-statement© Sociedad de Biologia de Chile 2024
==== Body
pmcIntroduction

Sex hormones, encompassing androgens secreted by the testes, estrogens produced by the ovaries, and progesterone (Pg) released from the corpus luteum, represent a class of hormones secreted by reproductive and other endocrine glands [1]. These hormones not only dictate sexual characteristics but also exert profound influences on various aspects of human health and metabolism, including the phenotypic switching of VSMCs [2–5].

Under physiological conditions, VSMCs exhibit a contractile phenotype characterized by low proliferative and synthetic activities [3]. However, upon exposure to factors such as hypoxia and inflammation, VSMCs demonstrate their remarkable plasticity by transitioning from this contractile phenotype to alternative phenotypes, a process defined as phenotypic switching of VSMCs. This transformation is accompanied by reduced synthesis of contraction-related proteins, concurrently promoting the upregulation of proinflammatory cytokines and matrix metalloproteinases (MMPs), thereby leading to increased cell migration, proliferation, and secretion [4]. This process plays a pivotal role in the initiation and progression of various cardiovascular diseases (CVDs) [5]. Consequently, a comprehensive understanding of VSMCs phenotypic switching and the promotion of favorable transitions towards beneficial phenotypes paves the way for novel strategies in the prevention and treatment of CVDs.

There is a mutual relationship between sex hormones and the phenotypic switching of VSMCs, which can impact vascular physiology and disease development. Studies have demonstrated that estrogen has a protective effect on VSMCs, as it can suppress their proliferation, migration, and phenotypic switching process [6–8]. This may be related to estrogen’s regulation of intracellular signaling pathways, such as through activation of phosphoinositide 3-kinase/serine/threonine kinase (PI3K/AKT) and extracellular regulated protein kinases 1/2 (ERK1/2) pathways [9]. In contrast, the effects of testosterone (T) on VSMCs are more complex. T can promote VSMCs proliferation and phenotypic transition, increasing the thickness of the vascular wall muscle layer [10]. This may involve T’s regulation of cell cycle proteins and related signaling pathways to influence cell proliferation and differentiation. However, the phenomenon described here only scratches the surface of the effects of sex hormones. In recent years, some scholars have discovered that sex hormones seem to possess dual effects, as they can promote or inhibit VSMCs proliferation, migration, and phenotypic conversion under different conditions [8, 11, 12]. We delve into this topic with greater detail in the following sections.

In summary, sex hormones play an important role in regulating phenotypic switching of VSMCs, but their specific effects are regulated by multiple factors, such as hormone levels, receptor expression, and the interplay of intracellular signaling pathways [8]. These regulatory processes are crucial for maintaining vascular structure and function, as well as for impacting the development of vascular diseases such as atherosclerosis and hypertension. This review thoroughly explores the relationship between sex hormones and phenotypic switching of VSMCs, aiming to provide deeper insights into vascular physiology and disease development mechanisms, and to offer new ideas and strategies for the treatment and prevention of related diseases.

Physiological function of vascular smooth muscle

The healthy arteries are composed of three-layered ring structures: the intima consisting of a monolayer of endothelial cells, the media containing multiple layers of VSMCs and an elastic fiber layer in between, while the adventitia comprises fibroblasts, adipocytes, connective tissue, and extracellular matrix(ECM) [5].

Mature VSMCs, distinct from their terminally differentiated counterparts in skeletal and cardiac muscle, exhibit remarkable plasticity. Upon differentiation, VSMCs adopt a characteristic fusiform, stable contractile phenotype and specifically express an array of contractile markers, including but not limited to alpha-smooth muscle actin (α-SMA), myosin heavy chain 11 (MYH11), transgelin (TAGLN), smoothelin, and calponin 1 (CNN1), as documented in references [13–15]. However, in response to environmental changes or vascular disease risk factors, such as hypercholesterolemia, hypertension, hyperglycemia, aging, and smoking, VSMCs demonstrate adaptive phenotypic transitions, shifting from a contractile to diverse alternative phenotypes. This process is accompanied by upregulated expression of signaling molecules intimately associated with cell growth, migration, fibrosis, and inflammation, for instance, osteopontin (OPN), desmin, and vimentin, as reported in [16].

The mechanisms underlying VSMCs phenotypic modulation are intricate and are orchestrated by intricate regulatory networks involving gene transcription, epigenetic modifications, and signaling transduction pathways. At the transcriptional level, serum response factor (SRF) and its core cofactor, myocardin (MYOCD), constitute the cornerstone of VSMCs phenotypic regulation. By specifically binding to CArG box sequences within 5’ promoters and intronic regions, SRF activates the expression of VSMCs-specific contractile genes [17]. Furthermore, PTEN, a downstream effector of SRF, enhances SRF’s ability to engage critical promoter elements of VSMCs contractile genes through their interaction, a mechanism thoroughly explored in [18, 19]. Additionally, Krüppel-like factor 4 (KLF4) [20], forkhead box O4 [21], transcription factor ELK-1 [22] and octamer-binding transcription factor 4 [23] play indispensable roles in transcriptional regulation. In the realm of epigenetic modifications, MicroRNAs (miRNAs) profoundly influence VSMCs phenotypic transitions through post-transcriptional mechanisms. Specifically, miRNAs such as miR-1, miR-21, miR-143/145, miR-133, miR-124, miR-370, miR-24, and miR-29a have been shown to drive VSMCs differentiation [24–26], whereas miR-24, miR-26a, miR-146a, miR-206, miR-221, and miR-222 facilitate dedifferentiation and proliferation post-vascular injury [26–28]. Moreover, emerging studies have revealed the involvement of non-coding RNAs, including circMAP3K5, circDcbld1, and circLrp6, in regulating VSMCs phenotypic modulation [29–31]. At the signaling pathway level, multiple signaling cascades converge to orchestrate VSMCs phenotypic transitions. Notably, Ras/Raf/MEK/ERK, GSK3β, and β-catenin signaling pathways promote VSMCs phenotypic modulation, whereas Rho-actin, TGF-β, and PI3K/Akt/mTOR signaling pathways exert inhibitory effects [32]. This intricate regulatory network ensures the functional adaptability and phenotypic plasticity of VSMCs under both physiological and pathological conditions. (Fig. 1)

Fig. 1 A: Vascular layering and cellular distribution within blood vessels, with VSMCs located in the tunica media. B: Differentiation and dedifferentiation markers of VSMCs. C: Mechanisms of VSMC phenotypic modulation

Phenotypic switching in VSMCs: a comprehensive classification

From a historical perspective, VSMCs have traditionally been thought to undergo a dichotomous phenotypic transition from their contractile state to a so-called “synthetic” state. This implies their responsiveness to various stimuli, switching to a synthetic state and reverting to a contractile state once stimulation ceases. Thus, the contractile and synthetic phenotypes were previously considered the “ideal” phenotypes [33]. However, concerted efforts by numerous scientists have now established that under specific conditions, contractile VSMCs can transition into diverse phenotypes, including intermediate, fibroblast-like, macrophage-like, osteogenic, and adipocyte-like VSMCs [34]. Consequently, the understanding of VSMCs phenotypes has evolved from a simple dichotomous model (contractile and synthetic) to a more complex polymorphic model. Recent research employing single-cell RNA sequencing(scRNA-seq) has revealed a “transitional phase” between contractile VSMCs and their derived cell types, termed modulated VSMCs, which have been implicated in the pathogenesis of atherosclerotic lesions [23, 35]. (Fig. 2)

Fig. 2 Phenotypic classification and characteristics of VSMCs. Under external stimuli, differentiated VSMCs show reduced expression of contraction markers, giving rise to modulatory and dedifferentiated VSMCs, which express corresponding phenotypic markers. This process influences VSMC proliferation and migration, contributing to the onset and progression of diseases

Modulated VSMCs

Currently, the characterization of modulated VSMCs predominantly focuses on three categories.

Pro-inflammatory macrophage-like phenotype characterized by Galectin-3 (LGALS3) expression

LGALS3 was initially believed to be a characteristic of VSMCs transitioning towards a terminally differentiated macrophage-like state, particularly in lesion cores [20, 36–38]. It was discovered by Alencar et al [23] to be transcriptionally activated in over 60% of VSMCs within atherosclerotic lesions in Myh11-DreERT2-Lgals3-Cre double recombinase Apolipoprotein E (APOE) mice models. Contrary to expectations, these LGALS3 + VSMCs did not differentiate into macrophages but instead displayed at least 4–5 distinct transcriptional profiles, ultimately leading to inflammatory or osteogenic cell states. This subset of LGALS3 + VSMCs exhibited similarities to the fibroblast-like cells previously characterized by Wirka et al [39]. Furthermore, Pan et al [35]. observed in atherosclerotic lesions in both humans and mice that LGALS3 + VSMCs have the ability to differentiate into various cell types, including intermediate cells expressing markers for stem cells, endothelial cells (ECs), and macrophages. Similarly, Hartmann et al [40]. utilized scRNA-seq analysis of lesioned regions in ApoE-deficient mice with SMC-specific deletion of Has3 to identify a notable population of LGALS3-expressing VSMCs. Notably, the emergence of this population has led to advantageous alterations within the lesions. These results collectively confirm LGALS3 as an indicator of the shift from contractile VSMCs to modulatory phenotypes.

Synthetic VSMCs

Under stimuli such as hypoxia, inflammation, and mechanical changes, VSMCs can undergo dedifferentiation and transition into a synthetic phenotype [41, 42]. The synthetic VSMCs exhibit a flattened fibroblast-like morphology with a significant increase in cell volume and a decrease in the content of myofilaments and structural proteins in the cytoplasm [43]. Functionally, the contractile ability of synthetic VSMCs weakens, while their proliferation, migration, and secretion capabilities significantly enhance [43]. At the molecular level, the expression of contractile markers is reduced in synthetic VSMCs, whereas the expression of secretion-related molecules, such as bone morphogenetic protein 2 (BMP-2), OPN, MMPs, and various inflammation-related cytokines, is significantly increased [43, 44].

The main function of synthetic VSMCs is to participate in the process of vascular reconstruction and repair. When the blood vessels are damaged or inflamed, these cells are activated and begin to synthesize and secrete ECM molecules, such as collagen, to repair the damaged vessel wall [45]. In addition, they can also produce and release growth factors, such as platelet-derived growth factor (PDGF) and TGF-β which promote the proliferation and migration of VSMCs, further promoting vascular reconstruction [46].

Mesenchymal-like VSMCs

Based on lineage tracing studies, contractile VSMCs can undergo a transition to a mesenchymal phenotype, acquiring proliferative and self-renewal abilities while exhibiting reduced expression of contractile proteins [20, 46, 47]. Researchers have defined spinocerebellar ataxia type 1 (SCA1)-expressing VSMCs as mesenchymal-like VSMCs, functioning similarly to mesenchymal stem cells [15]. In response to external stimulation, VSMCs differentiate from contractile to mesenchymal-like phenotypes through inducible repair and/or proliferation processes. KLF4 is considered a key initiator of this phenotypic switch, regulating cell proliferation and dedifferentiation [20, 32, 43, 48–56]. Induction of KLF4 expression leads to the transformation of VSMCs from a contractile to a mesenchymal-like state, characterized by the expression of mesenchyme markers SCA1/lymphocyte antigen 6 family member A (LY6A), CD34, and CD44 [54, 55]. Mesenchymal-like VSMCs are present in the intimal and adventitial layers of arteries [51, 56, 57] Following injury, mesenchymal-like VSMCs proliferate and migrate towards the media and intima, supporting tissue repair and potentially contributing to neointimal thickening [56, 58–60]. In vitro cultured VSMCs, as well as VSMCs subpopulations derived from carotid artery ligation and atherosclerotic plaques, exhibit increased expression of mesenchymal markers SCA1/LY6A [48]. Recent genetic studies indicate that SCA1/LY6A-positive VSMCs have limited impact on atherosclerotic neointima formation, highlighting their context-dependent and injury-specific nature [61]. Identifying human homologs of SCA1/LY6A may further elucidate the plasticity of mesenchymal-like VSMCs as a source of reparative VSMCs and determine their significance in vascular tissue regeneration in the context of vascular diseases [62].

Dedifferentiated VSMCs

Osteogenic VSMCs

During the process of ossification, hypertrophic chondrocytes transform into osteoblasts by generating specific ECM mineralization substances [63]. In the process of calcification associated with atherosclerosis [64] and multiple sclerosis [65], human VSMCs express type II collagen and exhibit a phenotype similar to chondrocytes, referred to as osteogenic VSMCs.

Characteristics of the osteogenic-like phenotype in VSMCs include the loss of contractile markers such as smooth muscle protein 22-α (SM22α) and actin alpha 2, as well as increased expression of calcification markers, such as the runt-related transcription factor 2 (RUNX2), the sry-box transcription factor 9, the zinc finger transcription factor Sp7/Osterix, and BMP-2 [48, 66–69]. Additionally, other markers such as OPN, osteocalcin, alkaline phosphatase (ALP), collagen type II, and collagen type X are also associated with the osteogenic-like phenotype in VSMCs [66, 70]. Both in vitro and in vivo experiments have demonstrated that RUNX2 plays a driving role in VSMCs osteogenesis, while the sry-box transcription factor 9 binds to RUNX2 and inhibits its function [71]. In osteogenic VSMCs, SP7/ Osterix enhances the expression of the RUNX2 gene through interaction and co-regulation of other genes, which is crucial for downstream osteoblast differentiation and bone formation [72]. BMPs are members of the TGF-β protein family, and BMP-2 has been shown to activate RUNX2 in various cell types, playing a critical role in bone repair [73].

AKT, as well as Jun N-terminal kinase(JNK), regulate the osteogenic process involving RUNX2. In human VSMCs exposed to calcifying media, the phosphorylation level of AKT decreases, while the activity of JNK transiently increases, consistent with the notion that elevated levels of AKT and JNK can prevent vascular calcification [74]. This process also involves Wnt signaling, in osteogenic-like VSMCs, Wnt activates β-catenin, which subsequently enters the nucleus and binds to DNA, enhancing the signaling of SP7/Osterix and BMP-2 to facilitate the osteogenic action of RUNX2 [75].

Macrophage-like VSMCs

Recent scRNA-seq studies have demonstrated that contractile VSMCs undergo a mesenchymal-like transition, becoming similar to macrophages, which is associated with the development of atherosclerosis [20, 76, 77].The presence of these macrophage-like cells is indicated by LGALS3 and classical macrophage markers, with LGALS3 and CD68 being the most common ones [46, 78]. Oxidized low-density lipoprotein (oxLDL) and high cholesterol are major metabolic factors underlying the occurrence of macrophage-like VSMCs [79, 80]. Exposure to high cholesterol can induce the transformation of VSMCs into macrophage-like VSMCs, with KLF4 playing a crucial role in this process [81]. OxLDL in the elderly promotes VSMCs to acquire macrophage phenotypes and functions [82]. On the contrary, high-density lipoprotein (HDL) exerts reverse effects by removing cholesterol from cells and transporting it to the liver for clearance of peripheral cholesterol. Under the influence of HDL, VSMCs increase the expression of MYOCD and miR-143/145, leading to a reduction in the macrophage-like VSMCs phenotype [81].

Fibroblast-like VSMCs

Recent scRNA-seq studies have revealed that in the context of vascular injury, such as the progression of atherosclerosis or the formation of aortic aneurysms, there is a collective phenotypic modulation of VSMCs [39, 83]. TCF21, a fundamental helix-loop-helix transcription factor, is expressed in epicardial progenitor cells during mouse cardiac development, playing a crucial role in the differentiation of fibroblasts and coronary artery smooth muscle cells [84, 85]. Wirka et al [39] utilized scRNA-seq analysis on SMC-specific TCF21 knockout mice in the aortic root and ascending aorta, demonstrating a significant decrease in phenotypic modulation capability and a notable reduction in fibroblast-like cells within lesion and protective fibrous cap regions. Subsequently, they verified that the expression of TCF21 in atherosclerotic lesions in both human and murine subjects is closely linked to the dedifferentiation of VSMCs towards a fibroblastic phenotype, potentially reducing the likelihood of developing coronary artery disease.

In contrast to VSMCs, fibroblast-like VSMCs express fibroblast-specific markers lumican, biglycan, and decorin, while levels of endogenous contractile markers (TAGLN, CNN1) are significantly reduced [39, 86]. Gene expression profiling revealed four major functions of fibroblast-like VSMCs based on scRNA-seq data: synthesizing the ECM, enhancing cell-matrix adhesion, promoting cell proliferation, and regulating collagen deposition [87]. The latter is considered a hallmark of aortic aneurysm formation, closely associated with aortic fibrosis and stiffening processes [87][.Fibroblast-like VSMCs and mesenchymal-like VSMCs share the characteristic marker SCA1/LY6A [39, 50, 86]. Exogenously derived fibroblast-like VSMCs expressing SCA1/LY6A can even migrate to the intimal layer, thereby promoting fibrotic reactions at that site and contributing to vascular wall stiffening [88]. In addition, cholesterol-induced VSMCs phenotypic switching also involves the development of fibroblast-like VSMCs [52, 54]. This transition is accompanied by upregulation of fibroblast-specific markers, including fibronectin 1, ecrg4 augurin precursor, proteoglycan 4, OPN, lipocalin-2, tissue inhibitor of metalloproteinase 1, biglycan, and decorin [54].

Adipocyte-like VSMCs

A scRNA-seq analysis has been the only way to describe the phenotype of adipocyte-like VSMCs [46]. This study, using constitutive or inducible Myh11-driven Cre mouse models, demonstrated the ability of VSMCs to adopt this adipocyte-like phenotype [89]. These adipocyte-like VSMCs, classified as beige adipocytes, are also referred to as inducible brown adipocytes [89]. They express key markers of beige adipocytes, including mitochondrial brown fat uncoupling protein 1, peroxisome proliferator-activated receptor gamma coactivator 1 alpha, transmembrane protein 26, domain-containing protein 16, and temperature-sensitive ion channel transient receptor potential cation channel subfamily V member 1 [89, 90]. Following 7 days of cold exposure, these cells can further mature into brown adipocyte-like VSMCs expressing uncoupling protein 1, adiponectin and type 2 iodothyronine deiodinase [89]. The conversion of contractile VSMCs to adipocyte-like VSMCs within the vascular wall may have consequences; however, due to limited research on this phenotype, further investigations are needed to understand its relevance.

The impact of sexual arousal on the phenotypic transformation markers of VSMCs. (Fig. 3)

Fig. 3 Switches for VSMC phenotypic transformation, estrogen and androgen acting on receptor proteins or other factors influencing the expression of synthetic and contractile markers, mediating VSMCs phenotypic transformation

Estrogen

Angiotensin II(Ang II)can decrease the expression of smooth muscle contraction markers and increase the expression of synthetic markers. Additionally, it can promote the migration of macrophages and their differentiation into osteoclast-like cells [91]. However, post-treatment with estrogen significantly inhibits the phenotypic transformation of VSMCs and exhibits a concentration dependence [92]. Studies have shown that estradiol (E2) upregulates the expression of ABCA1 and ABCG1 by interacting with estrogen receptor(ER) and liver X receptors α, significantly enhancing cholesterol efflux to APOE and HDL. At the same time, it weakens the accumulation of cholesterol esters in VSMCs induced by oxLDL and reduces foam cell formation derived from VSMCs [93].

Estrogen promotes autophagy in VSMCs through the estrogen receptor alpha(ERα) signaling pathway, reducing the expression of differentiation marker RUNX2 and ALP activity, thereby inhibiting the osteogenic differentiation of VSMCs [94]. Studies have found that activating ERα reduces the expression of differentiation markers in aortic smooth muscle cells [95]. In addition, inhibiting ERα, estrogen receptor beta(ERβ), and/or G-protein-coupled estrogen receptor(GPR30) can reduce the expression of VSMCs calponin [96]. Moreover, MYOCD is a cardiac and smooth muscle cell-specific protein that can activate multiple VSMCs differentiation markers [97]. The interaction of MYOCD with the coactivator steroid receptor coactivator 3 of ER can upregulate the expression of VSMCs differentiation markers [97]. Similarly, MYOCD can induce the transcription and expression of SM22α and α-SMA in rat uterine VSMCs, but when combined with ERα and CArG box, ERα can inhibit this effect [98]. CD34 + VRS/Pcs in the vascular adventitia was first reported by Hu et al [58]. Estrogen has a dual effect on CD34 + VRS/Pcs. Cells in an undifferentiated state are accelerated in their proliferation by pELK1-SRF complex binds to the c-fos promoter and increases transcription. When VSMCs are stimulated, it promotes differentiation through the mechanism of interaction between the MYOCD-SRF complex mediated by coactivator steroid receptor coactivator 3 and the SM22 gene [99].

Estrogen-related receptor γ is a subtype of ER that promotes VSMCs’ dedifferentiation from an osteogenic phenotype during the process of vascular calcification [100]. GPR30 is another type of ER that maintains VSMCs’ synthetic phenotype by activating the ERK1/2 and AKT pathways. It may play a role in the pathogenesis of LDL-induced adventitial calcification and therefore can serve as a new therapeutic target [9].

Androgen

Recent research has revealed the multifaceted mechanisms through which testosterone regulates the phenotypic transition of VSMCs [10]. In comparison to previous studies, our investigation has demonstrated a more pronounced inhibitory effect of T on oxLDL-induced VSMCs proliferation. Specifically, T induces cell cycle arrest predominantly at the G0/G1 phase and significantly enhances the expression levels of Mitofusin-2 and α-SMA. Furthermore, within a certain dosage range, a slight dose-dependent increase in the expression levels of p-ERK1/2, proliferating cell nuclear antigen, proliferating cell nuclear antigen and OPN was observed [101]. These findings shed light on novel mechanisms by which T governs VSMCs phenotypic regulation.

In inflammatory diseases, androgen receptor (AR) plays a significant role in monocytes/macrophages. By employing AR-silenced culture media to inhibit macrophages, we discovered that it could alleviate inorganic phosphate-induced calcification of human aortic smooth muscle cells (HASMCs) and impede their osteogenic differentiation. This is attributed to the decreased protein expression of osteoblast marker RUNX2 and the increased expression of VSMCs marker SM22α in AR-silenced conditions within the HASMCs [102]. Additionally, we propose that AR’s impact on HASMC calcification may be primarily mediated through the inflammatory cytokine IL-6. Silencing AR in monocytes/macrophages resulted in a significant reduction in IL-6 expression [102]. Immunohistochemical analysis revealed the presence of AR expression in human iliac artery tissue and the calcification media of calcified valves. In vitro studies of VSMCs have revealed that T and dihydrotestosterone (DHT) significantly increase the expression of the mineralization key regulator ALP mRNA. Researchers isolated VSMCs from AR-deficient mice and exposed them to testosterone, observing increased Osterix mRNA expression and upregulation of ALP expression. This finding further underscores that androgen-stimulated VSMCs calcification is mediated through the AR [103].

Progesterone (Pg)

One of the primary cellular events in vascular calcification is the osteogenic differentiation of VSMCs [104]. Researchers cultured VSMCs in osteogenic media with or without Pg for 21 days. Compared to the control group, treatment with Pg or Medroxyprogesterone Acetate significantly suppressed VSMCs ALP activity and calcium deposition. Further investigations revealed that Pg and Medroxyprogesterone Acetate inhibit VSMCs osteogenic transition through Pg receptor mediation [105]. However, their actions differ when applied to osteoblasts, where Pg promotes maturation and mineralization [105]. This controversial outcome stems from osteoblasts’s potent ability to metabolize Pg into different relevant compounds [106], resulting in progesterone’s dual role: inhibiting calcification in VSMCs while promoting maturation and mineralization in osteoblasts.

Mechanisms of sex hormone regulation on VSMCs phenotypic switching (Fig. 4)

Fig. 4 Estrogen and androgen regulate VSMCs proliferation, migration, and participate in disease formation and development. Four classic signaling pathways, MAPK/ERK, Ras-pRb, PI3K/AKT, and DNA methylation/histone modification, enable estrogen and androgen to activate or silence relevant proteins by promoting or inhibiting protein phosphorylation and enhancing methylation, thereby affecting VSMCs proliferation, migration, and phenotypic transformation, driving disease progression

Receptor-mediated signaling pathway

Estrogens inhibit the proliferation and migration of VSMCs [107, 108], thereby delaying the formation and development of arterial plaques, mainly through the classical MAPK/ERK, Ras-pRb, and PI3K/AKT pathways.

MAPK/ERK pathway

ERK1/2 plays a critical role in cell proliferation by exerting its effects through nuclear localization and phosphorylation of transcription factors [109]. Its activity follows a biphasic pattern, characterized by a rapid increase and peak followed by a sustained but lower level during the G phase. This biphasic pattern is crucial for promoting cell progression from G1 to S phase, involving both rapid non-genomic effects and persistent genomic effects [110]. However, whether there are gene expression-independent effects remains to be further investigated. Experimental results in rat VSMCs demonstrate that E2 induces cell proliferation by promoting ERK1/2 phosphorylation [111]. Conversely, when using the GPR30 agonist G-1, it inhibits ERK1/2 phosphorylation in mouse, human, and pig VSMCs, thereby suppressing cell proliferation, migration, and differentiation [112]. Interestingly, other studies have also found that estrogen-induced ERK1/2 phosphorylation may inhibit proliferation and migration of rat aortic VSMCs [9, 113]. This effect appears to be associated with estrogen-induced upregulation of calponin, a calcium-dependent supporting protein [114].

Although these results may seem contradictory, a thorough investigation into the underlying molecular mechanisms may help unravel this puzzle. In fact, in HASMCs, activation of ERα inhibits persistent ERK phosphorylation by upregulating manganese superoxide dismutase, thereby suppressing cell proliferation [115]. Therefore, we can conclude that estrogen induces transient phosphorylation of ERK1/2, allowing VSMCs to enter the cell cycle and express calponin, followed by the inhibition of persistent ERK1/2 phosphorylation in the biphasic pattern.

Specifically, we postulate that estrogen may have a dual regulatory effect on VSMCs function. On one hand, under normal physiological conditions, estrogen inhibits VSMCs proliferation and migration. On the other hand, under pathological circumstances, estrogen can activate the ERK pathway to promote VSMCs proliferation and growth. This activation has also been documented to potentially involve the selective activation or inhibition of ERα through GPR30 [9, 112], p38 MAPK [116], or under high-glucose conditions [115].

The Ras-pRb pathway

The retinoblastoma protein (pRb) plays a crucial role in cell proliferation. It is a tumor suppressor protein that regulates the cell cycle by inhibiting E2F transcription factors in a hypophosphorylated state under quiescent conditions [117]. Phosphorylation of pRb is one of the most critical steps for regulating cell cycle progression. Studies have shown that E2 can inhibit PDGF-induced pRb phosphorylation. This effect is mediated by ERα but is independent of ERβ [118]. Additionally, Estrogen-related receptor alpha prevent excessive phosphorylation of pRb, leading to the suppression of rat aortic VSMCs proliferation and neointima formation after vascular injury. These effects may involve the action of the cell cycle-dependent kinase inhibitor p27 Kip1 [119]. By suppressing the activity of CDK2, CDK4/6, 2-methoxyestradiol (2-ME) can maintain the hypophosphorylated state of pRb, inhibit cell entry into S phase, hinder DNA synthesis, and ultimately suppress VSMCs proliferation and neointimal formation [120]. Furthermore, E2 can delay premature senescence of VSMCs in young female rats by inhibiting the Ras-pRb pathway. However, in aged rats, it may promote senescence. Selective blockade of ER accelerates aging in rats [121]. These findings suggest that estrogen replacement therapy has a protective effect on the vasculature of young women, while the use of estrogen replacement therapy in postmenopausal elderly women may carry potential risks.

PI3K/AKT pathway

AKT is considered as an integral component of the PI3K/AKT signaling pathway, which has been extensively studied in various cell types and shown to play a critical role in cell proliferation, survival, and metabolism [122]. In VSMCs, activated AKT can suppress the expression of genes related to muscle contraction while promoting the expression of genes involved in synthesis, thus facilitating the phenotypic transformation of VSMCs. Sex hormones can regulate the phenotypic transition of VSMCs intracellularly, and this process may involve the activation of the PI3K/AKT signaling pathway [123]. Studies have found that in VSMCs isolated from human and pig carotid arteries, estrogen stimulation of GPR30 can inhibit cell proliferation by reducing AKT phosphorylation levels and inducing p21 expression. P21 is a cyclin-dependent kinase inhibitor that induces G1/S phase cell cycle arrest [124]. Additionally, estrogen downregulates SIRT1, promoting VSMCs apoptosis and inhibiting proliferation by inhibiting AKT and ERK phosphorylation [125] Recent research has also revealed that E2 inhibits the proliferation and migration of VSMCs by modulating AKT activity [126].

In HASMCs, testosterone stimulation promotes the expression of growth arrest-specific gene 6 and inhibits vascular calcification through the activation of the AKT signaling pathway [127]. Conversely, research has shown that ginsenoside Rb1 can hinder cell proliferation and calcification under testosterone stimulation by suppressing the AKT signaling pathway [128]. These findings suggest that androgens may have dual effects, highlighting the importance of understanding how to harness the beneficial effects of androgens in future research endeavors.

Furthermore, the PI3K/AKT pathway interacts with other signaling pathways to collectively regulate smooth muscle phenotypic transition. For example, there is reciprocal regulation between the PI3K/AKT pathway and the RhoA/ROCK pathway [129]. This interaction further regulates processes such as cell cytoskeleton reorganization, cell adhesion, and cell migration, which have significant impacts on smooth muscle phenotypic transition.

DNA methylation and histone modifications

Given that estrogen exerts its effects through binding to its receptors, epigenetic regulation of these receptors may play a crucial role in estrogen-mediated modulation of VSMCs phenotypic switching [130, 131]. In fact, the ER-α promoter is almost unmodified by methylation in normal aortic tissue, whereas it is highly methylated in synthetic VSMCs isolated from human aortas. This high level of methylation contributes significantly to VSMCs phenotypic transition. Other studies have shown that the high degree of methylation of ERα is associated with atherosclerosis and ischemic stroke, and the severity of the disease is positively correlated with the degree of methylation [132–134]. Further research has confirmed this association, revealing that insulin can promote the expression of DNA methyltransferase, leading to an increase in ER methylation [135]. Increased endoplasmic reticulum methylation leads to reduced expression of ERα in VSMCs, resulting in uncontrolled proliferation and promoting the progression of atherosclerosis [135].

In addition, estrogen can also regulate the expression of the SRF gene through ERα-mediated long non-coding RNA, thereby inhibiting smooth muscle phenotypic transition in VSMCs [136]. On the other hand, androgens promote VSMCs phenotypic transition by enhancing the interaction between the glucocorticoid receptor and CpG methyltransferase 1, increasing the level of DNA methylation modification [137].

The regulatory role of sex hormones in smooth muscle phenotype transition-mediated diseases

Vascular aging (Fig. 5)

Fig. 5 Mechanisms by which estrogen and androgen contribute to vascular aging, vascular calcification, and atherosclerosis onset and development

Vascular aging is characterized by decreased vascular elasticity, increased vascular wall thickness, impaired endothelial function, increased inflammation and arteriosclerosis, and decreased repairability [138]. This process is mainly influenced by the activation of the pro-inflammatory pathway, oxidative stress, cell senescence, and VSMCs proliferation phenotypes. Studies have shown that estrogen slows down the aging process of blood vessels by promoting Rab9-dependent mitochondrial autophagy, reducing oxidative stress and inflammatory reactions, and decreasing vascular wall thickness and stiffness [139].

Previous studies have reported that ERα and ERβ are expressed in the vascular system of both humans and animals, including endothelial and VSMCs [6]. Both ECs and VSMCs are affected by E2, however, their functional roles differ significantly. E2 enhances resistance to injuries in endothelial cells and plays a crucial role in beneficial effects such as enhancing endothelial nitric oxide production, endothelialization, intimal hyperplasia, and atherosclerosis. These actions are primarily mediated through ERα rather than ERβ [140]. In contrast, E2 has minimal pro-angiogenic effects in VSMCs and instead inhibits proliferation and migration by activating VSMCs nuclear ERα-AF1, ultimately preventing neointima formation [141]. In an accelerated aging model, the ERα protein level in the inner layer of the aorta decreases [142]. However, another study found no difference in ERα levels in primary cultures of aortic VSMCs from young (10 weeks) and middle-aged (12 months) mice [143], indicating that further comprehensive research is needed to investigate the age-related changes in ERα expression in VSMCs.

Chen et al. employed T therapy in an Ang II-induced VSMC aging model and found that T delayed VSMCs senescence by reducing MMP2 activity and suppressing collagen synthesis, mediated through the Gas6/AXL and AKT/FOXO1a signaling pathways [144]. Similarly, vascular aging diminishes the expression of calcium-activated potassium channels in VSMCs [145]. Zhou et al [146] discovered that endogenous T deprivation led to downregulation of Kv1.5 expression in rat thoracic aorta VSMCs, while T replacement therapy restored impaired Kv function. This suggests that T may delay vascular aging by activating Kv function in VSMCs. Interestingly, Chignalia et al [147] found that T induces accumulation of reactive oxygen species in VSMCs, reducing NO bioavailability and thereby attenuating vascular relaxation responses. English et al [148] studying arteries of male Wistar rats at different ages, observed that aged vessels are less responsive to T-mediated vasodilation compared to younger counterparts, accompanied by VSMCs hypertrophy and thickening of the smooth muscle layer. The uncertain effects of T on vascular tone regulation may be concentration-dependent, with vasodilation observed only at supraphysiological doses/concentrations [149].

Vascular calcification (Fig. 5)

Vascular calcification is a complex and dynamic process regulated by multiple factors [150]. It primarily occurs in the media and intima of arteries and involves various types of vascular cells [150]. Among them, VSMCs play a key role in the process of vascular calcification and undergo transformation into osteoblast-like cells. This transformation is characterized by the loss of contractile markers and the acquisition of markers associated with osteoblasts [151, 152].

Studies have shown that estrogen plays an important protective role in maintaining vascular health and inhibiting vascular calcification. It suppresses calcium deposition by regulating cytokines and calcium ion balance. Estrogen therapy can reduce the expression of hypoxia-inducible factor-1α, regulate BMP-2 and downstream signaling pathway Smad1/5/8, thereby reducing vascular calcification in rats [153]. Estrogen-related receptor γ induces the expression of BMP-2, increases the phosphorylation level of intracellular BMP-2 effector protein SMAD1/5/8, and upregulates the expression of osteogenic genes while downregulating the expression of a-SMA [100]. After ovariectomy, the lack of estrogen significantly increases the activity of L-type calcium channels in VSMCs, resulting in an elevation of intracellular calcium ion concentration and promoting vascular calcification [154]. Pg can bind to membrane Pg receptor α, activate the corresponding signaling pathway, and reduce calcium ion concentration in VSMCs [155].

On the other hand, elevated T levels are associated with the development of atherosclerosis and calcification of arteries. T may exert a protective effect on vascular calcification through the activation of protein kinase C signaling pathway and the non-transcriptional pathway of phosphatase, which enhances the activity of calcium pumps and reduces intracellular calcium ion concentration [156]. Moreover, Ginsenoside Rb1, a SARM, can activate the AR signaling pathway, enhance the activity of calcium pumps, reduce calcium ion deposition on the vascular wall, and inhibit vascular calcification [128].

Atherosclerosis (Fig. 5)

VSMCs are the main cell type found in the subendothelial layer of blood vessels and are responsible for synthesizing matrix molecules such as collagen fibers and elastic fibers, which maintain the structure and stability of the blood vessels. However, under certain conditions, VSMCs can undergo phenotypic switching, resulting in the secretion of large amounts of collagen and MMPs, which may contribute to the formation and progression of atherosclerosis.

Early studies have shown that estrogen has a protective effect against atherosclerosis [157]. It can reduce the oxidation of harmful low-density lipoprotein cholesterol and increase the levels of beneficial high-density lipoprotein cholesterol, thereby reducing the risk of plaque formation [157]. For example, oral estrogen therapy can lower low-density lipoprotein cholesterol levels, increase high-density lipoprotein cholesterol levels, and reduce cholesterol deposition on the vascular wall, ultimately lowering the risk of atherosclerosis [158]. However, the vascular protective effects of oral estrogen are still controversial. The Women’s Health Initiative study in 2002 showed that supplemental estrogen had no cardiovascular benefits and actually increased the risk of cardiovascular complications in postmenopausal women when used in conjunction with progestin [159]. Therefore, understanding the role of estrogen in cardiovascular disease is complex, as it may exert different effects in different tissues and be influenced by individual differences, age, and other factors.

In males, T has a dual nature in its effects. Studies have shown that T can prevent intimal thickening in atherosclerosis. It can protect against neointimal hyperplasia after coronary artery balloon injury and prevent the formation of new intimal plaques in the aorta after ex vivo stripping [160]. However, the DHT can lead to decreased arterial elasticity and arterial sclerosis in female mice, increasing the risk of CVDs [137]. Furthermore, as men age, T levels gradually decrease, which is associated with an increased risk of atherosclerotic CVDs, further emphasizing the complex relationship between sex hormones and atherosclerosis [161].

Abdominal aortic aneurysm(AAA) (Fig. 6)

Fig. 6 Mechanisms involving estrogen and androgen in abdominal aortic aneurysm

AAA is a pathological dilation of the infrarenal aorta that can lead to aortic wall rupture and catastrophic bleeding, resulting in high mortality rates [162]. At the histopathological level, AAA is characterized by SMC apoptosis, inflammatory cell accumulation, ECM degradation, and oxidative stress occurrence [162, 163]. Previous research has extensively demonstrated the significant role of hormonal factors in the occurrence, progression, and prognosis management of AAA. For instance, in mouse experimental models, estrogen has been shown to reduce inflammation and the expression of MMPs, while simultaneously increasing the expression of tissue inhibitors of metalloproteinases [164]. This leads to a decrease in VSMCs apoptosis, enhanced proliferation and collagen synthesis, ultimately increasing aortic stability and inhibiting the formation and progression of AAA [164]. Estrogen can also regulate the expression of TROVE2, inducing macrophage polarization towards an M2 phenotype. This plays an anti-inflammatory role within the tumor by enhancing macrophage phagocytosis and degradation of oxLDL, reducing ROS and VSMCs apoptosis, thereby inhibiting the occurrence and development of AAA [165]. Furthermore, estrogen can counteract the inhibitory effect of Ang II on mitochondrial membrane potential stability by regulating the expression of mitochondrial membrane channel proteins. This restores mitochondrial function, thereby impeding the development of AAA [166].Similarly, E2 can weaken the formation of Ang II-induced AAA in APOE-deficient mice. This is achieved by reducing the production of inflammatory factors and MMPs, as well as promoting VSMCs proliferation and collagen synthesis [167]. Moreover, in vivo exposure to E2 can suppress MMP2 activity in male VSMCs, leading to a reduction in the size and incidence of male AAA [168].

The phenotypic transition of VSMCs into osteoblast-like cells has been confirmed as a key factor in the occurrence and development of AAA [169]. Estrogen/Pg exert protective effects in premenopausal state, but this safeguard diminishes in postmenopausal state. The decline in estrogen’s protective efficacy has been substantiated across multiple laboratories, giving rise to the “timing hypothesis” [170]. As plasma estrogen levels decline and follicle-stimulating hormone (FSH) levels rise during early menopause [171, 172], attention has shifted towards the role of FSH. Tedjawirja et al. [173]. propose that prolonged elevated plasma FSH levels during the menopausal transition may directly and/or indirectly exacerbate the severity of AAA. They hypothesize that FSH stimulation could promote macrophage differentiation into osteoclast-like cells via TNFα, leading to the production of various proteases (e.g., MMP-9, tissue-type plasminogen activator K), thereby degrading aortic ECM and worsening AAA. Furthermore, FSH may enhance vascular cell adhesion molecule-1 expression in ECs, stimulating neovascularization and inflammation, thereby promoting AAA development. Additionally, FSH stimulates adipogenesis, increases hepatic cholesterol synthesis, promotes low-density lipoprotein accumulation, and exacerbates vascular dysfunction. However, these hypotheses require further validation in vivo and in vitro.

Male gender is an unmodifiable risk factor for the development of AAA. Previous studies have shown that exogenous DHT administration increases the abundance of AT1aR mRNA in the abdominal aorta and promotes Ang II-induced AAA in ApoE-deficient mice [174]. In the mouse model of Ang II-induced AAA, endogenous androgen deprivation results in decreased progressive luminal expansion, significantly alleviating the extent of AAA progression, and reducing both the size of the aneurysm and the degree of wall inflammation [175]. Inhibiting the production of 6β-Hydroxytestosterone or blocking its receptor binding can also significantly reduce inflammation and oxidative stress, inhibit VSMCs proliferation, and alleviate Ang II-induced abdominal aortic aneurysm [176]. Furthermore, activation of the AR increases the expression of inflammatory factors IL-1α, interferon - γ, IL-6, and IL-17, promoting abnormal VSMCs proliferation, leading to the formation and progression of AAA [177].

Pulmonary arterial hypertension(PAH) (Fig. 7)

Fig. 7 Changes in vascular smooth muscle in pulmonary arterial hypertension, and estrogen and androgen participation in the occurrence and development of pulmonary arterial hypertension by regulating vascular smooth muscle proliferation and migration

The definition of PAH is the formation of complex vascular lesions and vascular remodeling caused by accelerated proliferation of pulmonary ECs, VSMCs, and fibroblast cells [178]. In the early stages, pathologic VSMCs exhibit reduced differentiation, specifically characterized by downregulation of the MYH11 gene expression and upregulation of the PDGFR-β gene expression [179]. Furthermore, studies have also found that PDGFR-β precursor VSMCs upregulate the expression of the KLF4 gene through the PDGF-dependent pathway. To alleviate hypoxia-induced PAH, it is possible to achieve this by depleting KLF4 in VSMCs or depleting PDGF-BB in ECs and macrophages [180–182].

In the past decades, various studies have consistently described the dominant presence of female patients in the population with PAH. Therefore, investigating the unique role of estrogen in PAH is of particular importance. Indeed, mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene have been identified as one of the most common genetic factors in PAH, and females carrying BMPR2 gene mutations have a higher incidence of the disease [183]. Focusing on this phenomenon, research has found that estrogen can promote excessive proliferation of pulmonary arterial smooth muscle cells (PASMCs) by inhibiting BMPR2 expression [184–186]. This process is enhanced by ERα, which directly binds to the estrogen response elements on the BMPR2 gene promoter [184]. Both mRNA and protein expression levels of female BMPR2 have been observed to be lower in human and murine PASMCs compared to healthy controls and male counterparts [184]. This may partially explain why females are more susceptible to PAH [187]. Estrogen appears to be a “double-edged sword” as under certain conditions, it can also promote BMPR2 gene expression, thereby inhibiting adverse reactions such as proliferation of pulmonary arterial ECs, pulmonary vascular narrowing, and apoptosis of pulmonary arterial ECs, thus protecting right ventricular function [188]. Additionally, estrogen may exert its effects by upregulating the activity of other important mediators in PAH, such as the serotonin signaling pathway, which plays a critical role in the pathological processes of PAH, including promoting vasoconstriction, increasing platelet aggregation, and stimulating cell proliferation [189].

E2 is the most abundant and biologically active estrogen produced by the ovaries, capable of oxidation at multiple carbon positions including C2, C4, and C16. Hydroxylation at the C16 position leads to the formation of high estrogenic metabolites such as 16α-hydroxyestrone (16α-OHE), whereas hydroxylation at C2 results in 2-ME, which exhibits lower estrogenic activity [190]. Both metabolites have been implicated in the onset and progression of PAH. Elevated levels of 16α-OHE were initially observed in urine from female PAH patients with BMPR2 mutations as early as 2013 [191]. Subsequent clinical studies demonstrated that 16α-OHE significantly induces proliferation of PASMCs in PAH patients [192, 193]. Moreover, 16α-OHE stimulates excessive reactive oxygen species generation through NADPH oxidase induced by ERα, leading to oxidative inactivation of protein tyrosine phosphatase and abnormal PASMC proliferation via p38 mitogen-activated protein kinase signaling and cell cycle dysregulatio [194]. Conversely, in contrast to the detrimental effects of 16α-OHE, 2-ME has shown protective effects against PAH. For instance, GPR30 induces 2-ME to inhibit AT1R signaling, thereby suppressing abnormal proliferation in primary rat aortic VSMCs [195] and rat hepatic epithelial cell line [196]. These findings suggest that different estrogen metabolic pathways may exert varying impacts on PAH development.

In PAH, Dehydroepiandrosterone (DHEA) has also been described to have multifunctional protective effects. In human PASMCs, DHEA can exert antioxidant function by regulating mitochondria, thereby reducing proliferation and promoting apoptosis [197]. Consistent with this, DHEA reverses pulmonary artery remodeling through various mechanisms. For example, in an in vitro culture model of hypoxic PASMCs, DHEA treatment has been found to inhibit the accumulation of hypoxia-inducible factor-1α, alleviate proliferation and differentiation of PASMCs, and prevent the formation and progression of PAH [198]. DHEA can downregulate the expression of Src kinase and STAT3 in PASMCs from PAH patients, inhibit their downstream targets Pim1 and NFATc2 expression/activation, restore BMPR2 and miR-204, thereby alleviating adverse reactions such as pulmonary vascular narrowing and increased pulmonary vascular resistance [199].

Discussion

Sex hormones play a crucial role in regulating phenotypic transformation of VSMCs, involving multiple regulatory aspects. This study represents the first demonstration of how sex hormones influence the morphology, function, and physiological state of VSMCs through modulation of gene expression, signal transduction, and cytokines. Firstly, in terms of gene expression regulation, sex hormones bind with nuclear receptors (such as ERα and ERβ), forming receptor-hormone complexes that bind to hormone response elements on the genomic DNA, thereby influencing gene transcription and expression. These genes include key regulatory factors such as α-SMA and MYH11, which have significant effects on the phenotypic characteristics of VSMCs. Secondly, in terms of signal transduction pathways, sex hormones can regulate VSMCs phenotypic switching by activating or inhibiting Some important signaling pathways include the MAPK/ERK pathway, PI3K/AKT pathway, and Wnt/β-catenin pathway, among others. Moreover, sex hormones can also regulate the synthesis and release of various cytokines, which in turn influence the phenotypic switching of VSMCs. For instance, AR can block IL-6 production, which is involved in the process of VSMCs phenotypic switching.

The current investigation of VSMCs phenotypic transitions and the impact of sex hormones on these transitions is still in its early stages, necessitating further research. While the classification of VSMCs phenotypes has advanced to include modulated and dedifferentiated types, the understanding of modulated VSMCs lags behind that of types such as macrophage-like or osteogenic VSMCs, with limited depth in our comprehension. It is currently uncertain whether LGALS3 + VSMCs possess distinct functions in pathological conditions or if alternative biomarkers exist to indicate “transitional stage VSMCs”. Additionally, the presence of adipocyte-like VSMCs within the dedifferentiated classification has only been documented in a single study, with uncertainties surrounding their functions, the reasons for VSMCs undergoing adipocyte-like transformations, and the precise mechanisms involved.

Moreover, recent investigations into VSMCs phenotypes have validated phenotypic shifts in both arterial and venous VSMCs [95, 200]. Current research on sex hormones and CVDs tends to concentrate on arterial or carotid artery VSMCs, with limited attention given to venous VSMCs [95, 201]. Studies related to venous VSMCs typically focus on venous-related conditions like varicose veins, venous valve damage, and deep venous thrombosis [202–204]. Expanding upon the comprehensive overview provided earlier, the involvement of sex hormones in the phenotypes of arterial VSMCs in vivo or in primary cells and cell lines derived from human or mouse arterial or carotid artery VSMCs, whether in vitro, is of significant interest. It is hypothesized that venous VSMCs may exhibit a comparable significance, given the current evidence indicating that sex hormones prompt venous VSMCs to shift towards a synthetic phenotype [9]. Nevertheless, additional research is needed to determine if they have the potential to transition to alternative phenotypes. The deficiencies in these investigations highlight the extensive journey required to fully comprehend VSMCs phenotypic differentiation.

Through our research, we have partially elucidated the impact of sex hormones on VSMCs phenotype. However, the diverse mechanisms of action of sex hormones and their various receptor types pose complexities. Are the roles of different sex hormones in regulating VSMCs phenotype transition universally applicable? What are the precise signaling pathways and molecular mechanisms through receptors such as ERα, ERβ, and GPR30? Besides these pathways, are there other mechanisms influencing VSMCs phenotype transition? Our current investigations are primarily based on in vitro models, whereas in vivo environments are inherently more intricate. For instance, do significant fluctuations in sex hormone levels during physiological states like aging, puberty, pregnancy, and menopause affect VSMCs phenotype transition? Furthermore, throughout the lifespan, disparities exist in circulating sex hormone levels and types between males and females. How might these gender differences impact VSMC phenotype transition? Additionally, reproductive endocrine disorders have become a focal point of study; women affected by these disorders exhibit disrupted sex hormone expression, with existing literature indicating an increased risk of CVDs among such patients [205]. Do VSMCs phenotypes change in these patients, and if so, what specific alterations occur? Addressing these questions is poised to advance our understanding of VSMCs phenotype transition and the mechanisms of action of sex hormones.

VSMCs exhibit notable phenotypic plasticity, granting them considerable regenerative potential. Therefore, the precise regulation of their phenotype is essential for mitigating the substantial health impact of CVDs. Due to the varied functions of distinct VSMCs phenotypes in different cardiovascular conditions, a comprehensive comprehension of the functional characteristics and specific mechanisms governing VSMCs phenotype transitions is increasingly imperative. This not only assists in identifying potential advantageous aspects of diseases but also enables the advancement of novel disease intervention approaches.

Conclusion

Through a systematic examination of recent studies on sex hormones and VSMCs phenotype modulation, we have elucidated the crucial role of sex hormones in governing VSMCs phenotype switching and consequent disease advancement. We provide a comprehensive overview of the diverse mechanisms by which sex hormones impact VSMCs phenotype transition. Although there are still many unanswered questions, our research has established a foundation for the discovery of new regulatory factors, signaling pathways, and potential targets related to the modulation of VSMCs phenotype. This offers promising avenues for further exploration and the development of novel therapeutic interventions.

Acknowledgements

Not applicable.

Author contributions

Keran Jia and Xin Luo contributed equally in preparing the original draft of the manuscript. Jingyan Yi and Chunxiang Zhang guided the entire study.

Funding

This work was supported by National Science Foundation of China (U23A20398, 82030007, 82301845); China Postdoctoral Science Foundation (2023M732929); Luzhou Science and Technology Project (2023SYF111).

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors have read the manuscript and agreed to submit the paper for publication.

Competing interests

There are no conflicts to declare. Figures were created by Figdraw (www.figdraw.com).

Abbreviations

VSMCs Vascular Smooth Muscle Cells

Pg Progesterone

MMPs Matrix Metalloproteinases

CVDs Cardiovascular Diseases

PI3K/AKT Phosphoinositide 3-kinase/serine/threonine kinase

ERK1/2 Extracellular Regulated Protein Kinases 1/2

T Testosterone

ECM Extracellular Matrix

α-SMA Alpha-Smooth Muscle Actin

MYH11 Myosin Heavy Chain 11

TAGLN Transgelin

CNN1 Calponin 1

OPN Osteopontin

SRF Serum Response Factor

MYOCD Myocardin

KLF4 Krüppel-Like Factor 4

miRNAs MicroRNAs

scRNA-seq Single-cell RNA sequencing

LGALS3 Galectin-3

APOE Apolipoprotein E

ECs Endothelial Cells

BMP-2 Bone Morphogenetic Protein 2

PDGF Platelet-Derived Growth Factor

SCA1 Spinocerebellar Ataxia Type 1

LY6A Lymphocyte Antigen 6 Family Member A

SM22α Smooth Muscle Protein 22-α

RUNX2 Runt-Related Transcription Factor 2

ALP Alkaline Phosphatase

JNK Jun N-terminal Kinase

oxLDL Oxidized Low-density Lipoprotein

HDL High-Density Lipoprotein

Ang II Angiotensin II

E2 Estradiol

ER Estrogen Receptor

ERα Estrogen Receptor alpha

ERβ Estrogen Receptor beta

GPR30 G-Protein-coupled estrogen Receptor

AR Androgen Receptor

HASMCs Human Aortic Smooth Muscle Cells

DHT Dihydrotestosterone

pRb Retinoblastoma Protein

2-ME 2-methoxyestradiol

AAA Abdominal Aortic Aneurysm

PAH Pulmonary Arterial Hypertension

BMPR2 Bone Morphogenetic Protein Receptor type 2

PASMCs Pulmonary Arterial Smooth Muscle Cells

16α-OHE 16α-hydroxyestrone

DHEA Dehydroepiandrosterone

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Keran Jia and Xin Luo contributed equally to this work.
==== Refs
References

1. Naamneh Elzenaty R du Toit T Fluck CE Basics of androgen synthesis and action Best Pract Res Clin Endocrinol Metab 2022 36 4 101665 10.1016/j.beem.2022.101665 35595638
Naamneh Elzenaty R, du Toit T, Fluck CE. Basics of androgen synthesis and action. Best Pract Res Clin Endocrinol Metab. 2022;36(4):101665. 10.1016/j.beem.2022.101665.35595638 10.1016/j.beem.2022.101665
2. Miao CY Li ZY The role of perivascular adipose tissue in vascular smooth muscle cell growth Br J Pharmacol 2012 165 3 643 58 10.1111/j.1476-5381.2011.01404.x 21470202
Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol. 2012;165(3):643–58. 10.1111/j.1476-5381.2011.01404.x.21470202 10.1111/j.1476-5381.2011.01404.x
3. Sorokin V Vickneson K Kofidis T Woo CC Lin XY Foo R Role of vascular smooth muscle cell plasticity and interactions in Vessel Wall inflammation Front Immunol 2020 11 599415 10.3389/fimmu.2020.599415 33324416
Sorokin V, Vickneson K, Kofidis T, Woo CC, Lin XY, Foo R, et al. Role of vascular smooth muscle cell plasticity and interactions in Vessel Wall inflammation. Front Immunol. 2020;11:599415. 10.3389/fimmu.2020.599415.33324416 10.3389/fimmu.2020.599415
4. Song J Wan Y Rolfe BE Campbell JH Campbell GR Effect of estrogen on vascular smooth muscle cells is dependent upon cellular phenotype Atherosclerosis 1998 140 1 97 104 10.1016/s0021-9150(98)00122-1 9733220
Song J, Wan Y, Rolfe BE, Campbell JH, Campbell GR. Effect of estrogen on vascular smooth muscle cells is dependent upon cellular phenotype. Atherosclerosis. 1998;140(1):97–104. 10.1016/s0021-9150(98)00122-1.9733220 10.1016/s0021-9150(98)00122-1
5. Touyz RM Alves-Lopes R Rios FJ Camargo LL Anagnostopoulou A Arner A Vascular smooth muscle contraction in hypertension Cardiovasc Res 2018 114 4 529 39 10.1093/cvr/cvy023 29394331
Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A, et al. Vascular smooth muscle contraction in hypertension. Cardiovasc Res. 2018;114(4):529–39. 10.1093/cvr/cvy023.29394331 10.1093/cvr/cvy023
6. Mendelsohn ME Karas RH Estrogen and the blood vessel wall Curr Opin Cardiol 1994 9 5 619 26 10.1097/00001573-199409000-00018 7987043
Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol. 1994;9(5):619–26. 10.1097/00001573-199409000-00018.7987043 10.1097/00001573-199409000-00018
7. Dehaini H Fardoun M Abou-Saleh H El-Yazbi A Eid AA Eid AH Estrogen in vascular smooth muscle cells: a friend or a foe? Vascul Pharmacol 2018 111 15 21 10.1016/j.vph.2018.09.001 30227233
Dehaini H, Fardoun M, Abou-Saleh H, El-Yazbi A, Eid AA, Eid AH. Estrogen in vascular smooth muscle cells: a friend or a foe? Vascul Pharmacol. 2018;111:15–21. 10.1016/j.vph.2018.09.001.30227233 10.1016/j.vph.2018.09.001
8. Ruehlmann DO Mann GE Actions of oestrogen on vascular endothelial and smooth-muscle cells Biochem Soc Trans 1997 25 1 40 5 10.1042/bst0250040 9056840
Ruehlmann DO, Mann GE. Actions of oestrogen on vascular endothelial and smooth-muscle cells. Biochem Soc Trans. 1997;25(1):40–5. 10.1042/bst0250040.9056840 10.1042/bst0250040
9. Zha B Qiu P Zhang C Li X Chen Z GPR30 promotes the phenotypic switching of vascular smooth muscle cells via activating the AKT and ERK pathways Onco Targets Ther 2020 13 3801 8 10.2147/OTT.S244128 32440148
Zha B, Qiu P, Zhang C, Li X, Chen Z. GPR30 promotes the phenotypic switching of vascular smooth muscle cells via activating the AKT and ERK pathways. Onco Targets Ther. 2020;13:3801–8. 10.2147/OTT.S244128.32440148 10.2147/OTT.S244128
10. Kopp J Collin O Villar M Mullins D Bergh A Hokfelt T Regulation of neuropeptide Y Y1 receptors by testosterone in vascular smooth muscle cells in rat testis Neuroendocrinology 2008 88 3 216 26 10.1159/000138250 18535365
Kopp J, Collin O, Villar M, Mullins D, Bergh A, Hokfelt T. Regulation of neuropeptide Y Y1 receptors by testosterone in vascular smooth muscle cells in rat testis. Neuroendocrinology. 2008;88(3):216–26. 10.1159/000138250.18535365 10.1159/000138250
11. Yerly A van der Vorst EPC Baumgartner I Bernhard SM Schindewolf M Doring Y Sex-specific and hormone-related differences in vascular remodelling in atherosclerosis Eur J Clin Invest 2023 53 1 e13885 10.1111/eci.13885 36219492
Yerly A, van der Vorst EPC, Baumgartner I, Bernhard SM, Schindewolf M, Doring Y. Sex-specific and hormone-related differences in vascular remodelling in atherosclerosis. Eur J Clin Invest. 2023;53(1):e13885. 10.1111/eci.13885.36219492 10.1111/eci.13885
12. Stone JC MacDonald MJ The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: a narrative review Vascul Pharmacol 2023 152 107209 10.1016/j.vph.2023.107209 37591444
Stone JC, MacDonald MJ. The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: a narrative review. Vascul Pharmacol. 2023;152:107209. 10.1016/j.vph.2023.107209.37591444 10.1016/j.vph.2023.107209
13. Owens GK Kumar MS Wamhoff BR Molecular regulation of vascular smooth muscle cell differentiation in development and disease Physiol Rev 2004 84 3 767 801 10.1152/physrev.00041.2003 15269336
Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84(3):767–801. 10.1152/physrev.00041.2003.15269336 10.1152/physrev.00041.2003
14. Rensen SS Doevendans PA van Eys GJ Regulation and characteristics of vascular smooth muscle cell phenotypic diversity Neth Heart J 2007 15 3 100 8 10.1007/BF03085963 17612668
Rensen SS, Doevendans PA, van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 2007;15(3):100–8. 10.1007/BF03085963.17612668 10.1007/BF03085963
15. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg. 2007;45 Suppl A(6):A25-32. 10.1016/j.jvs.2007.03.001
16. Gao H Steffen MC Ramos KS Osteopontin regulates alpha-smooth muscle actin and calponin in vascular smooth muscle cells Cell Biol Int 2012 36 2 155 61 10.1042/CBI20100240 22032345
Gao H, Steffen MC, Ramos KS. Osteopontin regulates alpha-smooth muscle actin and calponin in vascular smooth muscle cells. Cell Biol Int. 2012;36(2):155–61. 10.1042/CBI20100240.22032345 10.1042/CBI20100240
17. McDonald OG Wamhoff BR Hoofnagle MH Owens GK Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo J Clin Invest 2006 116 1 36 48 10.1172/JCI26505 16395403
McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest. 2006;116(1):36–48. 10.1172/JCI26505.16395403 10.1172/JCI26505
18. Long X Bell RD Gerthoffer WT Zlokovic BV Miano JM Myocardin is sufficient for a smooth muscle-like contractile phenotype Arterioscler Thromb Vasc Biol 2008 28 8 1505 10 10.1161/ATVBAHA.108.166066 18451334
Long X, Bell RD, Gerthoffer WT, Zlokovic BV, Miano JM. Myocardin is sufficient for a smooth muscle-like contractile phenotype. Arterioscler Thromb Vasc Biol. 2008;28(8):1505–10. 10.1161/ATVBAHA.108.166066.18451334 10.1161/ATVBAHA.108.166066
19. Horita HN Simpson PA Ostriker A Furgeson S Van Putten V Weiser-Evans MC Serum response factor regulates expression of phosphatase and tensin homolog through a microRNA network in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 2011 31 12 2909 19 10.1161/ATVBAHA.111.233585 21940949
Horita HN, Simpson PA, Ostriker A, Furgeson S, Van Putten V, Weiser-Evans MC, et al. Serum response factor regulates expression of phosphatase and tensin homolog through a microRNA network in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011;31(12):2909–19. 10.1161/ATVBAHA.111.233585.21940949 10.1161/ATVBAHA.111.233585
20. Shankman LS Gomez D Cherepanova OA Salmon M Alencar GF Haskins RM KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis Nat Med 2015 21 6 628 37 10.1038/nm.3866 25985364
Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015;21(6):628–37. 10.1038/nm.3866.25985364 10.1038/nm.3866
21. Van Der Heide LP Hoekman MF Smidt MP The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation Biochem J 2004 380 Pt 2 297 309 10.1042/BJ20040167 15005655
Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 2004;380(Pt 2):297–309. 10.1042/BJ20040167.15005655 10.1042/BJ20040167
22. Wamhoff BR Hoofnagle MH Burns A Sinha S McDonald OG Owens GK A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis Circ Res 2004 95 10 981 8 10.1161/01.RES.0000147961.09840.fb 15486317
Wamhoff BR, Hoofnagle MH, Burns A, Sinha S, McDonald OG, Owens GK. A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res. 2004;95(10):981–8. 10.1161/01.RES.0000147961.09840.fb.15486317 10.1161/01.RES.0000147961.09840.fb
23. Alencar GF Owsiany KM Karnewar S Sukhavasi K Mocci G Nguyen AT Stem cell pluripotency genes Klf4 and Oct4 regulate Complex SMC phenotypic changes critical in late-stage atherosclerotic lesion pathogenesis Circulation 2020 142 21 2045 59 10.1161/CIRCULATIONAHA.120.046672 32674599
Alencar GF, Owsiany KM, Karnewar S, Sukhavasi K, Mocci G, Nguyen AT, et al. Stem cell pluripotency genes Klf4 and Oct4 regulate Complex SMC phenotypic changes critical in late-stage atherosclerotic lesion pathogenesis. Circulation. 2020;142(21):2045–59. 10.1161/CIRCULATIONAHA.120.046672.32674599 10.1161/CIRCULATIONAHA.120.046672
24. Tang Y Yu S Liu Y Zhang J Han L Xu Z MicroRNA-124 controls human vascular smooth muscle cell phenotypic switch via Sp1 Am J Physiol Heart Circ Physiol 2017 313 3 H641 9 10.1152/ajpheart.00660.2016 28667053
Tang Y, Yu S, Liu Y, Zhang J, Han L, Xu Z. MicroRNA-124 controls human vascular smooth muscle cell phenotypic switch via Sp1. Am J Physiol Heart Circ Physiol. 2017;313(3):H641–9. 10.1152/ajpheart.00660.2016.28667053 10.1152/ajpheart.00660.2016
25. Torella D Iaconetti C Catalucci D Ellison GM Leone A Waring CD MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo Circ Res 2011 109 8 880 93 10.1161/CIRCRESAHA.111.240150 21852550
Torella D, Iaconetti C, Catalucci D, Ellison GM, Leone A, Waring CD, et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res. 2011;109(8):880–93. 10.1161/CIRCRESAHA.111.240150.21852550 10.1161/CIRCRESAHA.111.240150
26. Davis-Dusenbery BN Wu C Hata A Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation Arterioscler Thromb Vasc Biol 2011 31 11 2370 7 10.1161/ATVBAHA.111.226670 22011749
Davis-Dusenbery BN, Wu C, Hata A. Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol. 2011;31(11):2370–7. 10.1161/ATVBAHA.111.226670.22011749 10.1161/ATVBAHA.111.226670
27. Sun H Cai S Zhang M Zhao J Wei S Luo Y MicroRNA-206 regulates vascular smooth muscle cell phenotypic switch and vascular neointimal formation Cell Biol Int 2017 41 7 739 48 10.1002/cbin.10768 28328152
Sun H, Cai S, Zhang M, Zhao J, Wei S, Luo Y, et al. MicroRNA-206 regulates vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Cell Biol Int. 2017;41(7):739–48. 10.1002/cbin.10768.28328152 10.1002/cbin.10768
28. Liu X Cheng Y Zhang S Lin Y Yang J Zhang C A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia Circ Res 2009 104 4 476 87 10.1161/CIRCRESAHA.108.185363 19150885
Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 2009;104(4):476–87. 10.1161/CIRCRESAHA.108.185363.19150885 10.1161/CIRCRESAHA.108.185363
29. Zeng Z Xia L Fan S Zheng J Qin J Fan X Circular RNA CircMAP3K5 acts as a MicroRNA-22-3p sponge to Promote Resolution of Intimal Hyperplasia Via TET2-Mediated smooth muscle cell differentiation Circulation 2021 143 4 354 71 10.1161/CIRCULATIONAHA.120.049715 33207953
Zeng Z, Xia L, Fan S, Zheng J, Qin J, Fan X, et al. Circular RNA CircMAP3K5 acts as a MicroRNA-22-3p sponge to Promote Resolution of Intimal Hyperplasia Via TET2-Mediated smooth muscle cell differentiation. Circulation. 2021;143(4):354–71. 10.1161/CIRCULATIONAHA.120.049715.33207953 10.1161/CIRCULATIONAHA.120.049715
30. Rong ZH Chang NB Yao QP Li T Zhu XL Cao Y Suppression of circDcbld1 alleviates Intimal Hyperplasia in Rat Carotid artery by targeting miR-145-3p/Neuropilin-1 Mol Ther Nucleic Acids 2019 18 999 1008 10.1016/j.omtn.2019.10.023 31778958
Rong ZH, Chang NB, Yao QP, Li T, Zhu XL, Cao Y, et al. Suppression of circDcbld1 alleviates Intimal Hyperplasia in Rat Carotid artery by targeting miR-145-3p/Neuropilin-1. Mol Ther Nucleic Acids. 2019;18:999–1008. 10.1016/j.omtn.2019.10.023.31778958 10.1016/j.omtn.2019.10.023
31. Hall IF Climent M Quintavalle M Farina FM Schorn T Zani S Circ_Lrp6, a circular RNA enriched in vascular smooth muscle cells, acts as a sponge regulating miRNA-145 function Circ Res 2019 124 4 498 510 10.1161/CIRCRESAHA.118.314240 30582454
Hall IF, Climent M, Quintavalle M, Farina FM, Schorn T, Zani S, et al. Circ_Lrp6, a circular RNA enriched in vascular smooth muscle cells, acts as a sponge regulating miRNA-145 function. Circ Res. 2019;124(4):498–510. 10.1161/CIRCRESAHA.118.314240.30582454 10.1161/CIRCRESAHA.118.314240
32. Frismantiene A Philippova M Erne P Resink TJ Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity Cell Signal 2018 52 48 64 10.1016/j.cellsig.2018.08.019 30172025
Frismantiene A, Philippova M, Erne P, Resink TJ. Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity. Cell Signal. 2018;52:48–64. 10.1016/j.cellsig.2018.08.019.30172025 10.1016/j.cellsig.2018.08.019
33. Tian L Chen K Cao J Han Z Wang Y Gao L Galectin–3 induces the phenotype transformation of human vascular smooth muscle cells via the canonical wnt signaling Mol Med Rep 2017 15 6 3840 6 10.3892/mmr.2017.6429 28393190
Tian L, Chen K, Cao J, Han Z, Wang Y, Gao L, et al. Galectin–3 induces the phenotype transformation of human vascular smooth muscle cells via the canonical wnt signaling. Mol Med Rep. 2017;15(6):3840–6. 10.3892/mmr.2017.6429.28393190 10.3892/mmr.2017.6429
34. Yap C Mieremet A de Vries CJM Micha D de Waard V Six shades of vascular smooth muscle cells illuminated by KLF4 (Kruppel-Like factor 4) Arterioscler Thromb Vasc Biol 2021 41 11 2693 707 10.1161/ATVBAHA.121.316600 34470477
Yap C, Mieremet A, de Vries CJM, Micha D, de Waard V. Six shades of vascular smooth muscle cells illuminated by KLF4 (Kruppel-Like factor 4). Arterioscler Thromb Vasc Biol. 2021;41(11):2693–707. 10.1161/ATVBAHA.121.316600.34470477 10.1161/ATVBAHA.121.316600
35. Pan H Xue C Auerbach BJ Fan J Bashore AC Cui J Single-cell Genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human Circulation 2020 142 21 2060 75 10.1161/CIRCULATIONAHA.120.048378 32962412
Pan H, Xue C, Auerbach BJ, Fan J, Bashore AC, Cui J, et al. Single-cell Genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. Circulation. 2020;142(21):2060–75. 10.1161/CIRCULATIONAHA.120.048378.32962412 10.1161/CIRCULATIONAHA.120.048378
36. Feil S Fehrenbacher B Lukowski R Essmann F Schulze-Osthoff K Schaller M Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis Circ Res 2014 115 7 662 7 10.1161/CIRCRESAHA.115.304634 25070003
Feil S, Fehrenbacher B, Lukowski R, Essmann F, Schulze-Osthoff K, Schaller M, et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ Res. 2014;115(7):662–7. 10.1161/CIRCRESAHA.115.304634.25070003 10.1161/CIRCRESAHA.115.304634
37. Allahverdian S Chehroudi AC McManus BM Abraham T Francis GA Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis Circulation 2014 129 15 1551 9 10.1161/CIRCULATIONAHA.113.005015 24481950
Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014;129(15):1551–9. 10.1161/CIRCULATIONAHA.113.005015.24481950 10.1161/CIRCULATIONAHA.113.005015
38. Wang Y Dubland JA Allahverdian S Asonye E Sahin B Jaw JE Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (apolipoprotein E)-Deficient mouse atherosclerosis Arterioscler Thromb Vasc Biol 2019 39 5 876 87 10.1161/ATVBAHA.119.312434 30786740
Wang Y, Dubland JA, Allahverdian S, Asonye E, Sahin B, Jaw JE, et al. Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (apolipoprotein E)-Deficient mouse atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(5):876–87. 10.1161/ATVBAHA.119.312434.30786740 10.1161/ATVBAHA.119.312434
39. Wirka RC Wagh D Paik DT Pjanic M Nguyen T Miller CL Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis Nat Med 2019 25 8 1280 9 10.1038/s41591-019-0512-5 31359001
Wirka RC, Wagh D, Paik DT, Pjanic M, Nguyen T, Miller CL, et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. Nat Med. 2019;25(8):1280–9. 10.1038/s41591-019-0512-5.31359001 10.1038/s41591-019-0512-5
40. Hartmann F Gorski DJ Newman AAC Homann S Petz A Owsiany KM SMC-Derived Hyaluronan modulates vascular SMC phenotype in murine atherosclerosis Circ Res 2021 129 11 992 1005 10.1161/CIRCRESAHA.120.318479 34615369
Hartmann F, Gorski DJ, Newman AAC, Homann S, Petz A, Owsiany KM, et al. SMC-Derived Hyaluronan modulates vascular SMC phenotype in murine atherosclerosis. Circ Res. 2021;129(11):992–1005. 10.1161/CIRCRESAHA.120.318479.34615369 10.1161/CIRCRESAHA.120.318479
41. Xiao X Liu YZ Cheng ZB Sun JX Shao YD Qu SL Adipokines in vascular calcification Clin Chim Acta 2021 516 15 26 10.1016/j.cca.2021.01.009 33476587
Xiao X, Liu YZ, Cheng ZB, Sun JX, Shao YD, Qu SL, et al. Adipokines in vascular calcification. Clin Chim Acta. 2021;516:15–26. 10.1016/j.cca.2021.01.009.33476587 10.1016/j.cca.2021.01.009
42. Kyotani Y, Takasawa S, Yoshizumi M. Proliferative pathways of vascular smooth muscle cells in response to intermittent hypoxia. Int J Mol Sci. 2019;20(11). 10.3390/ijms20112706.
43. Zhao D Li J Xue C Feng K Liu L Zeng P TL1A inhibits atherosclerosis in apoe-deficient mice by regulating the phenotype of vascular smooth muscle cells J Biol Chem 2020 295 48 16314 27 10.1074/jbc.RA120.015486 32963108
Zhao D, Li J, Xue C, Feng K, Liu L, Zeng P, et al. TL1A inhibits atherosclerosis in apoe-deficient mice by regulating the phenotype of vascular smooth muscle cells. J Biol Chem. 2020;295(48):16314–27. 10.1074/jbc.RA120.015486.32963108 10.1074/jbc.RA120.015486
44. Tierney JW Evans BC Cheung-Flynn J Wang B Colazo JM Polcz ME Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch JCI Insight 2021 6 19 e142339 10.1172/jci.insight.142339 34622803
Tierney JW, Evans BC, Cheung-Flynn J, Wang B, Colazo JM, Polcz ME, et al. Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch. JCI Insight. 2021;6(19):e142339. 10.1172/jci.insight.142339.34622803 10.1172/jci.insight.142339
45. Vatner SF Zhang J Vyzas C Mishra K Graham RM Vatner DE Vascular stiffness in aging and disease Front Physiol 2021 12 762437 10.3389/fphys.2021.762437 34950048
Vatner SF, Zhang J, Vyzas C, Mishra K, Graham RM, Vatner DE. Vascular stiffness in aging and disease. Front Physiol. 2021;12:762437. 10.3389/fphys.2021.762437.34950048 10.3389/fphys.2021.762437
46. Chen PY, Qin L, Li G, Malagon-Lopez J, Wang Z, Bergaya S et al. Smooth Muscle Cell Reprogramming in Aortic Aneurysms. Cell Stem Cell. 2020;26(4):542 – 57 e11. 10.1016/j.stem.2020.02.013
47. Nolasco P Fernandes CG Ribeiro-Silva JC Oliveira PVS Sacrini M de Brito IV Impaired vascular smooth muscle cell force-generating capacity and phenotypic deregulation in Marfan Syndrome mice Biochim Biophys Acta Mol Basis Dis 2020 1866 1 165587 10.1016/j.bbadis.2019.165587 31678158
Nolasco P, Fernandes CG, Ribeiro-Silva JC, Oliveira PVS, Sacrini M, de Brito IV, et al. Impaired vascular smooth muscle cell force-generating capacity and phenotypic deregulation in Marfan Syndrome mice. Biochim Biophys Acta Mol Basis Dis. 2020;1866(1):165587. 10.1016/j.bbadis.2019.165587.31678158 10.1016/j.bbadis.2019.165587
48. Dobnikar L Taylor AL Chappell J Oldach P Harman JL Oerton E Disease-relevant transcriptional signatures identified in individual smooth muscle cells from healthy mouse vessels Nat Commun 2018 9 1 4567 10.1038/s41467-018-06891-x 30385745
Dobnikar L, Taylor AL, Chappell J, Oldach P, Harman JL, Oerton E, et al. Disease-relevant transcriptional signatures identified in individual smooth muscle cells from healthy mouse vessels. Nat Commun. 2018;9(1):4567. 10.1038/s41467-018-06891-x.30385745 10.1038/s41467-018-06891-x
49. Wang C Han M Zhao XM Wen JK Kruppel-like factor 4 is required for the expression of vascular smooth muscle cell differentiation marker genes induced by all-trans retinoic acid J Biochem 2008 144 3 313 21 10.1093/jb/mvn068 18511453
Wang C, Han M, Zhao XM, Wen JK. Kruppel-like factor 4 is required for the expression of vascular smooth muscle cell differentiation marker genes induced by all-trans retinoic acid. J Biochem. 2008;144(3):313–21. 10.1093/jb/mvn068.18511453 10.1093/jb/mvn068
50. Garvey SM Sinden DS Schoppee Bortz PD Wamhoff BR Cyclosporine up-regulates Kruppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo J Pharmacol Exp Ther 2010 333 1 34 42 10.1124/jpet.109.163949 20089806
Garvey SM, Sinden DS, Schoppee Bortz PD, Wamhoff BR. Cyclosporine up-regulates Kruppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo. J Pharmacol Exp Ther. 2010;333(1):34–42. 10.1124/jpet.109.163949.20089806 10.1124/jpet.109.163949
51. Majesky MW Horita H Ostriker A Lu S Regan JN Bagchi A Differentiated smooth muscle cells generate a subpopulation of Resident Vascular Progenitor cells in the Adventitia regulated by Klf4 Circ Res 2017 120 2 296 311 10.1161/CIRCRESAHA.116.309322 27834190
Majesky MW, Horita H, Ostriker A, Lu S, Regan JN, Bagchi A, et al. Differentiated smooth muscle cells generate a subpopulation of Resident Vascular Progenitor cells in the Adventitia regulated by Klf4. Circ Res. 2017;120(2):296–311. 10.1161/CIRCRESAHA.116.309322.27834190 10.1161/CIRCRESAHA.116.309322
52. Yoshida T Kaestner KH Owens GK Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury Circ Res 2008 102 12 1548 57 10.1161/CIRCRESAHA.108.176974 18483411
Yoshida T, Kaestner KH, Owens GK. Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury. Circ Res. 2008;102(12):1548–57. 10.1161/CIRCRESAHA.108.176974.18483411 10.1161/CIRCRESAHA.108.176974
53. Alexander MR Owens GK Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease Annu Rev Physiol 2012 74 13 40 10.1146/annurev-physiol-012110-142315 22017177
Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74:13–40. 10.1146/annurev-physiol-012110-142315.22017177 10.1146/annurev-physiol-012110-142315
54. Chattopadhyay A Kwartler CS Kaw K Li Y Kaw A Chen J Cholesterol-Induced phenotypic modulation of Smooth Muscle Cells to Macrophage/Fibroblast-like cells is driven by an unfolded protein response Arterioscler Thromb Vasc Biol 2021 41 1 302 16 10.1161/ATVBAHA.120.315164 33028096
Chattopadhyay A, Kwartler CS, Kaw K, Li Y, Kaw A, Chen J, et al. Cholesterol-Induced phenotypic modulation of Smooth Muscle Cells to Macrophage/Fibroblast-like cells is driven by an unfolded protein response. Arterioscler Thromb Vasc Biol. 2021;41(1):302–16. 10.1161/ATVBAHA.120.315164.33028096 10.1161/ATVBAHA.120.315164
55. Zhao G Lu H Chang Z Zhao Y Zhu T Chang L Single-cell RNA sequencing reveals the cellular heterogeneity of aneurysmal infrarenal abdominal aorta Cardiovasc Res 2021 117 5 1402 16 10.1093/cvr/cvaa214 32678909
Zhao G, Lu H, Chang Z, Zhao Y, Zhu T, Chang L, et al. Single-cell RNA sequencing reveals the cellular heterogeneity of aneurysmal infrarenal abdominal aorta. Cardiovasc Res. 2021;117(5):1402–16. 10.1093/cvr/cvaa214.32678909 10.1093/cvr/cvaa214
56. Tang J Wang H Huang X Li F Zhu H Li Y Arterial Sca1(+) vascular stem cells generate De Novo Smooth Muscle for Artery Repair and regeneration Cell Stem Cell 2020 26 1 81 e964 10.1016/j.stem.2019.11.010 31883835
Tang J, Wang H, Huang X, Li F, Zhu H, Li Y, et al. Arterial Sca1(+) vascular stem cells generate De Novo Smooth Muscle for Artery Repair and regeneration. Cell Stem Cell. 2020;26(1):81–e964. 10.1016/j.stem.2019.11.010.31883835 10.1016/j.stem.2019.11.010
57. Sartore S Chiavegato A Faggin E Franch R Puato M Ausoni S Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant Circ Res 2001 89 12 1111 21 10.1161/hh2401.100844 11739275
Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res. 2001;89(12):1111–21. 10.1161/hh2401.100844.11739275 10.1161/hh2401.100844
58. Hu Y Zhang Z Torsney E Afzal AR Davison F Metzler B Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice J Clin Invest 2004 113 9 1258 65 10.1172/JCI19628 15124016
Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest. 2004;113(9):1258–65. 10.1172/JCI19628.15124016 10.1172/JCI19628
59. Passman JN Dong XR Wu SP Maguire CT Hogan KA Bautch VL A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1 + smooth muscle progenitor cells Proc Natl Acad Sci U S A 2008 105 27 9349 54 10.1073/pnas.0711382105 18591670
Passman JN, Dong XR, Wu SP, Maguire CT, Hogan KA, Bautch VL, et al. A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1 + smooth muscle progenitor cells. Proc Natl Acad Sci U S A. 2008;105(27):9349–54. 10.1073/pnas.0711382105.18591670 10.1073/pnas.0711382105
60. Kramann R Goettsch C Wongboonsin J Iwata H Schneider RK Kuppe C Adventitial MSC-like cells are progenitors of vascular smooth muscle cells and drive vascular calcification in chronic kidney disease Cell Stem Cell 2016 19 5 628 42 10.1016/j.stem.2016.08.001 27618218
Kramann R, Goettsch C, Wongboonsin J, Iwata H, Schneider RK, Kuppe C, et al. Adventitial MSC-like cells are progenitors of vascular smooth muscle cells and drive vascular calcification in chronic kidney disease. Cell Stem Cell. 2016;19(5):628–42. 10.1016/j.stem.2016.08.001.27618218 10.1016/j.stem.2016.08.001
61. Wang H Zhao H Zhu H Li Y Tang J Li Y Sca1(+) cells minimally contribute to smooth muscle cells in atherosclerosis Circ Res 2021 128 1 133 5 10.1161/CIRCRESAHA.120.317972 33146591
Wang H, Zhao H, Zhu H, Li Y, Tang J, Li Y, et al. Sca1(+) cells minimally contribute to smooth muscle cells in atherosclerosis. Circ Res. 2021;128(1):133–5. 10.1161/CIRCRESAHA.120.317972.33146591 10.1161/CIRCRESAHA.120.317972
62. Holmes C Stanford WL Concise review: stem cell antigen-1: expression, function, and enigma Stem Cells 2007 25 6 1339 47 10.1634/stemcells.2006-0644 17379763
Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells. 2007;25(6):1339–47. 10.1634/stemcells.2006-0644.17379763 10.1634/stemcells.2006-0644
63. Wolff LI Hartmann C A second Career for chondrocytes-Transformation into osteoblasts Curr Osteoporos Rep 2019 17 3 129 37 10.1007/s11914-019-00511-3 30949840
Wolff LI, Hartmann C. A second Career for chondrocytes-Transformation into osteoblasts. Curr Osteoporos Rep. 2019;17(3):129–37. 10.1007/s11914-019-00511-3.30949840 10.1007/s11914-019-00511-3
64. van Andel MM Groenink M Zwinderman AH de Mulder BJM The potential Beneficial effects of Resveratrol on Cardiovascular complications in Marfan Syndrome Patients(-)Insights from Rodent-Based Animal studies Int J Mol Sci 2019 20 5 1122 10.3390/ijms20051122 30841577
van Andel MM, Groenink M, Zwinderman AH, de Mulder BJM. The potential Beneficial effects of Resveratrol on Cardiovascular complications in Marfan Syndrome Patients(-)Insights from Rodent-Based Animal studies. Int J Mol Sci. 2019;20(5):1122. 10.3390/ijms20051122.30841577 10.3390/ijms20051122
65. Iqbal F Lupieri A Aikawa M Aikawa E Harnessing single-cell RNA sequencing to Better Understand how diseased cells behave the way they do in Cardiovascular Disease Arterioscler Thromb Vasc Biol 2021 41 2 585 600 10.1161/ATVBAHA.120.314776 33327741
Iqbal F, Lupieri A, Aikawa M, Aikawa E. Harnessing single-cell RNA sequencing to Better Understand how diseased cells behave the way they do in Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2021;41(2):585–600. 10.1161/ATVBAHA.120.314776.33327741 10.1161/ATVBAHA.120.314776
66. Durham AL Speer MY Scatena M Giachelli CM Shanahan CM Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness Cardiovasc Res 2018 114 4 590 600 10.1093/cvr/cvy010 29514202
Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res. 2018;114(4):590–600. 10.1093/cvr/cvy010.29514202 10.1093/cvr/cvy010
67. Voelkl J Lang F Eckardt KU Amann K Kuro OM Pasch A Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia Cell Mol Life Sci 2019 76 11 2077 91 10.1007/s00018-019-03054-z 30887097
Voelkl J, Lang F, Eckardt KU, Amann K, Kuro OM, Pasch A, et al. Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia. Cell Mol Life Sci. 2019;76(11):2077–91. 10.1007/s00018-019-03054-z.30887097 10.1007/s00018-019-03054-z
68. Yoshida CA Komori H Maruyama Z Miyazaki T Kawasaki K Furuichi T SP7 inhibits osteoblast differentiation at a late stage in mice PLoS ONE 2012 7 3 e32364 10.1371/journal.pone.0032364 22396760
Yoshida CA, Komori H, Maruyama Z, Miyazaki T, Kawasaki K, Furuichi T, et al. SP7 inhibits osteoblast differentiation at a late stage in mice. PLoS ONE. 2012;7(3):e32364. 10.1371/journal.pone.0032364.22396760 10.1371/journal.pone.0032364
69. Derwall M Malhotra R Lai CS Beppu Y Aikawa E Seehra JS Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis Arterioscler Thromb Vasc Biol 2012 32 3 613 22 10.1161/ATVBAHA.111.242594 22223731
Derwall M, Malhotra R, Lai CS, Beppu Y, Aikawa E, Seehra JS, et al. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(3):613–22. 10.1161/ATVBAHA.111.242594.22223731 10.1161/ATVBAHA.111.242594
70. Tyson KL Reynolds JL McNair R Zhang Q Weissberg PL Shanahan CM Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification Arterioscler Thromb Vasc Biol 2003 23 3 489 94 10.1161/01.ATV.0000059406.92165.31 12615658
Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003;23(3):489–94. 10.1161/01.ATV.0000059406.92165.31.12615658 10.1161/01.ATV.0000059406.92165.31
71. Loebel C Czekanska EM Bruderer M Salzmann G Alini M Stoddart MJ In vitro osteogenic potential of human mesenchymal stem cells is predicted by Runx2/Sox9 ratio Tissue Eng Part A 2015 21 1–2 115 23 10.1089/ten.TEA.2014.0096 24980654
Loebel C, Czekanska EM, Bruderer M, Salzmann G, Alini M, Stoddart MJ. In vitro osteogenic potential of human mesenchymal stem cells is predicted by Runx2/Sox9 ratio. Tissue Eng Part A. 2015;21(1–2):115–23. 10.1089/ten.TEA.2014.0096.24980654 10.1089/ten.TEA.2014.0096
72. Nakashima K Zhou X Kunkel G Zhang Z Deng JM Behringer RR The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation Cell 2002 108 1 17 29 10.1016/s0092-8674(01)00622-5 11792318
Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108(1):17–29. 10.1016/s0092-8674(01)00622-5.11792318 10.1016/s0092-8674(01)00622-5
73. Montezano AC Zimmerman D Yusuf H Burger D Chignalia AZ Wadhera V Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium Hypertension 2010 56 3 453 62 10.1161/HYPERTENSIONAHA.110.152058 20696983
Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension. 2010;56(3):453–62. 10.1161/HYPERTENSIONAHA.110.152058.20696983 10.1161/HYPERTENSIONAHA.110.152058
74. da Silva RA da Zambuzzi SFG Osteogenic gene markers are epigenetically reprogrammed during contractile-to-calcifying vascular smooth muscle cell phenotype transition Cell Signal 2020 66 109458 10.1016/j.cellsig.2019.109458 31678252
da Silva RA, da Zambuzzi SFG. Osteogenic gene markers are epigenetically reprogrammed during contractile-to-calcifying vascular smooth muscle cell phenotype transition. Cell Signal. 2020;66:109458. 10.1016/j.cellsig.2019.109458.31678252 10.1016/j.cellsig.2019.109458
75. Tyson J Bundy K Roach C Douglas H Ventura V Segars MF Mechanisms of the Osteogenic Switch of Smooth Muscle Cells in vascular calcification: WNT signaling, BMPs, mechanotransduction, and EndMT Bioeng (Basel) 2020 7 3 88 10.3390/bioengineering7030088
Tyson J, Bundy K, Roach C, Douglas H, Ventura V, Segars MF, et al. Mechanisms of the Osteogenic Switch of Smooth Muscle Cells in vascular calcification: WNT signaling, BMPs, mechanotransduction, and EndMT. Bioeng (Basel). 2020;7(3):88. 10.3390/bioengineering7030088.10.3390/bioengineering7030088
76. Bennett MR Sinha S Owens GK Vascular smooth muscle cells in atherosclerosis Circ Res 2016 118 4 692 702 10.1161/CIRCRESAHA.115.306361 26892967
Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692–702. 10.1161/CIRCRESAHA.115.306361.26892967 10.1161/CIRCRESAHA.115.306361
77. Cordes KR Sheehy NT White MP Berry EC Morton SU Muth AN miR-145 and miR-143 regulate smooth muscle cell fate and plasticity Nature 2009 460 7256 705 10 10.1038/nature08195 19578358
Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256):705–10. 10.1038/nature08195.19578358 10.1038/nature08195
78. Wolf MP Hunziker P Atherosclerosis: insights into Vascular Pathobiology and Outlook to Novel treatments J Cardiovasc Transl Res 2020 13 5 744 57 10.1007/s12265-020-09961-y 32072564
Wolf MP, Hunziker P. Atherosclerosis: insights into Vascular Pathobiology and Outlook to Novel treatments. J Cardiovasc Transl Res. 2020;13(5):744–57. 10.1007/s12265-020-09961-y.32072564 10.1007/s12265-020-09961-y
79. Andreeva ER Pugach IM Orekhov AN Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro Atherosclerosis 1997 135 1 19 27 10.1016/s0021-9150(97)00136-6 9395269
Andreeva ER, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis. 1997;135(1):19–27. 10.1016/s0021-9150(97)00136-6.9395269 10.1016/s0021-9150(97)00136-6
80. Rong JX Shapiro M Trogan E Fisher EA Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading Proc Natl Acad Sci U S A 2003 100 23 13531 6 10.1073/pnas.1735526100 14581613
Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A. 2003;100(23):13531–6. 10.1073/pnas.1735526100.14581613 10.1073/pnas.1735526100
81. Castiglioni S Monti M Arnaboldi L Canavesi M Ainis Buscherini G Calabresi L ABCA1 and HDL(3) are required to modulate smooth muscle cells phenotypic switch after cholesterol loading Atherosclerosis 2017 266 8 15 10.1016/j.atherosclerosis.2017.09.012 28946038
Castiglioni S, Monti M, Arnaboldi L, Canavesi M, Ainis Buscherini G, Calabresi L, et al. ABCA1 and HDL(3) are required to modulate smooth muscle cells phenotypic switch after cholesterol loading. Atherosclerosis. 2017;266:8–15. 10.1016/j.atherosclerosis.2017.09.012.28946038 10.1016/j.atherosclerosis.2017.09.012
82. Bao Z Li L Geng Y Yan J Dai Z Shao C Advanced Glycation End products induce vascular smooth muscle cell-derived foam cell formation and transdifferentiate to a macrophage-like State Mediators Inflamm 2020 2020 6850187 10.1155/2020/6850187 32831637
Bao Z, Li L, Geng Y, Yan J, Dai Z, Shao C, et al. Advanced Glycation End products induce vascular smooth muscle cell-derived foam cell formation and transdifferentiate to a macrophage-like State. Mediators Inflamm. 2020;2020:6850187. 10.1155/2020/6850187.32831637 10.1155/2020/6850187
83. Baum J Duffy HS Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol 2011 57 4 376 9 10.1097/FJC.0b013e3182116e39 21297493
Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol. 2011;57(4):376–9. 10.1097/FJC.0b013e3182116e39.21297493 10.1097/FJC.0b013e3182116e39
84. Dettman RW Denetclaw W Jr Ordahl CP Bristow J Common epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial fibroblasts in the avian heart Dev Biol 1998 193 2 169 81 10.1006/dbio.1997.8801 9473322
Dettman RW, Denetclaw W Jr., Ordahl CP, Bristow J. Common epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial fibroblasts in the avian heart. Dev Biol. 1998;193(2):169–81. 10.1006/dbio.1997.8801.9473322 10.1006/dbio.1997.8801
85. Winter EM Gittenberger-de Groot AC Epicardium-derived cells in cardiogenesis and cardiac regeneration Cell Mol Life Sci 2007 64 6 692 703 10.1007/s00018-007-6522-3 17380310
Winter EM, Gittenberger-de Groot AC. Epicardium-derived cells in cardiogenesis and cardiac regeneration. Cell Mol Life Sci. 2007;64(6):692–703. 10.1007/s00018-007-6522-3.17380310 10.1007/s00018-007-6522-3
86. Medley SC Rathnakar BH Georgescu C Wren JD Olson LE Fibroblast-specific Stat1 deletion enhances the myofibroblast phenotype during tissue repair Wound Repair Regen 2020 28 4 448 59 10.1111/wrr.12807 32175700
Medley SC, Rathnakar BH, Georgescu C, Wren JD, Olson LE. Fibroblast-specific Stat1 deletion enhances the myofibroblast phenotype during tissue repair. Wound Repair Regen. 2020;28(4):448–59. 10.1111/wrr.12807.32175700 10.1111/wrr.12807
87. Pedroza AJ Tashima Y Shad R Cheng P Wirka R Churovich S Single-cell transcriptomic profiling of vascular smooth muscle cell phenotype modulation in Marfan Syndrome aortic aneurysm Arterioscler Thromb Vasc Biol 2020 40 9 2195 211 10.1161/ATVBAHA.120.314670 32698686
Pedroza AJ, Tashima Y, Shad R, Cheng P, Wirka R, Churovich S, et al. Single-cell transcriptomic profiling of vascular smooth muscle cell phenotype modulation in Marfan Syndrome aortic aneurysm. Arterioscler Thromb Vasc Biol. 2020;40(9):2195–211. 10.1161/ATVBAHA.120.314670.32698686 10.1161/ATVBAHA.120.314670
88. Lu S Jolly AJ Strand KA Dubner AM Mutryn MF Moulton KS Smooth muscle-derived progenitor cell myofibroblast differentiation through KLF4 downregulation promotes arterial remodeling and fibrosis JCI Insight 2020 5 23 e139445 10.1172/jci.insight.139445 33119549
Lu S, Jolly AJ, Strand KA, Dubner AM, Mutryn MF, Moulton KS, et al. Smooth muscle-derived progenitor cell myofibroblast differentiation through KLF4 downregulation promotes arterial remodeling and fibrosis. JCI Insight. 2020;5(23):e139445. 10.1172/jci.insight.139445.33119549 10.1172/jci.insight.139445
89. Long JZ Svensson KJ Tsai L Zeng X Roh HC Kong X A smooth muscle-like origin for beige adipocytes Cell Metab 2014 19 5 810 20 10.1016/j.cmet.2014.03.025 24709624
Long JZ, Svensson KJ, Tsai L, Zeng X, Roh HC, Kong X, et al. A smooth muscle-like origin for beige adipocytes. Cell Metab. 2014;19(5):810–20. 10.1016/j.cmet.2014.03.025.24709624 10.1016/j.cmet.2014.03.025
90. Shamsi F Piper M Ho LL Huang TL Gupta A Streets A Vascular smooth muscle-derived Trpv1(+) progenitors are a source of cold-induced thermogenic adipocytes Nat Metab 2021 3 4 485 95 10.1038/s42255-021-00373-z 33846638
Shamsi F, Piper M, Ho LL, Huang TL, Gupta A, Streets A, et al. Vascular smooth muscle-derived Trpv1(+) progenitors are a source of cold-induced thermogenic adipocytes. Nat Metab. 2021;3(4):485–95. 10.1038/s42255-021-00373-z.33846638 10.1038/s42255-021-00373-z
91. Byon CH Sun Y Chen J Yuan K Mao X Heath JM Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages Arterioscler Thromb Vasc Biol 2011 31 6 1387 96 10.1161/ATVBAHA.110.222547 21454810
Byon CH, Sun Y, Chen J, Yuan K, Mao X, Heath JM, et al. Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol. 2011;31(6):1387–96. 10.1161/ATVBAHA.110.222547.21454810 10.1161/ATVBAHA.110.222547
92. Xia X Zhou C He X Liu C Wang G Sun X The relationship between estrogen-induced phenotypic transformation and proliferation of vascular smooth muscle and hypertensive intracerebral hemorrhage Ann Transl Med 2020 8 12 762 10.21037/atm-20-4567 32647687
Xia X, Zhou C, He X, Liu C, Wang G, Sun X. The relationship between estrogen-induced phenotypic transformation and proliferation of vascular smooth muscle and hypertensive intracerebral hemorrhage. Ann Transl Med. 2020;8(12):762. 10.21037/atm-20-4567.32647687 10.21037/atm-20-4567
93. Wang H Liu Y Zhu L Wang W Wan Z Chen F 17beta-estradiol promotes cholesterol efflux from vascular smooth muscle cells through a liver X receptor alpha-dependent pathway Int J Mol Med 2014 33 3 550 8 10.3892/ijmm.2014.1619 24398697
Wang H, Liu Y, Zhu L, Wang W, Wan Z, Chen F, et al. 17beta-estradiol promotes cholesterol efflux from vascular smooth muscle cells through a liver X receptor alpha-dependent pathway. Int J Mol Med. 2014;33(3):550–8. 10.3892/ijmm.2014.1619.24398697 10.3892/ijmm.2014.1619
94. Peng YQ Xiong D Lin X Cui RR Xu F Zhong JY Oestrogen inhibits arterial calcification by promoting Autophagy Sci Rep 2017 7 1 3549 10.1038/s41598-017-03801-x 28615727
Peng YQ, Xiong D, Lin X, Cui RR, Xu F, Zhong JY, et al. Oestrogen inhibits arterial calcification by promoting Autophagy. Sci Rep. 2017;7(1):3549. 10.1038/s41598-017-03801-x.28615727 10.1038/s41598-017-03801-x
95. Montague CR Hunter MG Gavrilin MA Phillips GS Goldschmidt-Clermont PJ Marsh CB Activation of estrogen receptor-alpha reduces aortic smooth muscle differentiation Circ Res 2006 99 5 477 84 10.1161/01.RES.0000238376.72592.a2 16873715
Montague CR, Hunter MG, Gavrilin MA, Phillips GS, Goldschmidt-Clermont PJ, Marsh CB. Activation of estrogen receptor-alpha reduces aortic smooth muscle differentiation. Circ Res. 2006;99(5):477–84. 10.1161/01.RES.0000238376.72592.a2.16873715 10.1161/01.RES.0000238376.72592.a2
96. Huang F Yin JG Li KY Li Y Qi H Fang L GPR30 decreases with vascular aging and promotes vascular smooth muscle cells maintaining differentiated phenotype and suppressing migration via activation of ERK1/2 Oncotargets Therapy 2016 9 3415 22 10.2147/Ott.S104972 27354813
Huang F, Yin JG, Li KY, Li Y, Qi H, Fang L, et al. GPR30 decreases with vascular aging and promotes vascular smooth muscle cells maintaining differentiated phenotype and suppressing migration via activation of ERK1/2. Oncotargets Therapy. 2016;9:3415–22. 10.2147/Ott.S104972.27354813 10.2147/Ott.S104972
97. Li HJ Haque Z Lu Q Li L Karas R Mendelsohn M Steroid receptor coactivator 3 is a coactivator for myocardin, the regulator of smooth muscle transcription and differentiation Proc Natl Acad Sci U S A 2007 104 10 4065 70 10.1073/pnas.0611639104 17360478
Li HJ, Haque Z, Lu Q, Li L, Karas R, Mendelsohn M. Steroid receptor coactivator 3 is a coactivator for myocardin, the regulator of smooth muscle transcription and differentiation. Proc Natl Acad Sci U S A. 2007;104(10):4065–70. 10.1073/pnas.0611639104.17360478 10.1073/pnas.0611639104
98. Liao XH Li JY Dong XM Wang X Xiang Y Li H ERalpha inhibited myocardin-induced differentiation in uterine fibroids Exp Cell Res 2017 350 1 73 82 10.1016/j.yexcr.2016.11.007 27871850
Liao XH, Li JY, Dong XM, Wang X, Xiang Y, Li H, et al. ERalpha inhibited myocardin-induced differentiation in uterine fibroids. Exp Cell Res. 2017;350(1):73–82. 10.1016/j.yexcr.2016.11.007.27871850 10.1016/j.yexcr.2016.11.007
99. Wu Y Shen Y Kang K Zhang Y Ao F Wan Y Effects of estrogen on growth and smooth muscle differentiation of vascular wall-resident CD34(+) stem/progenitor cells Atherosclerosis 2015 240 2 453 61 10.1016/j.atherosclerosis.2015.04.008 25898000
Wu Y, Shen Y, Kang K, Zhang Y, Ao F, Wan Y, et al. Effects of estrogen on growth and smooth muscle differentiation of vascular wall-resident CD34(+) stem/progenitor cells. Atherosclerosis. 2015;240(2):453–61. 10.1016/j.atherosclerosis.2015.04.008.25898000 10.1016/j.atherosclerosis.2015.04.008
100. Kim JH Choi YK Do JY Choi YK Ha CM Lee SJ Estrogen-related receptor gamma plays a key role in vascular calcification through the upregulation of BMP2 expression Arterioscler Thromb Vasc Biol 2015 35 11 2384 90 10.1161/ATVBAHA.115.306102 26404484
Kim JH, Choi YK, Do JY, Choi YK, Ha CM, Lee SJ, et al. Estrogen-related receptor gamma plays a key role in vascular calcification through the upregulation of BMP2 expression. Arterioscler Thromb Vasc Biol. 2015;35(11):2384–90. 10.1161/ATVBAHA.115.306102.26404484 10.1161/ATVBAHA.115.306102
101. Zhou W Liu W Liao H Cao Z Xie H Zhang S [Testosterone suppresses oxidized low-density lipoprotein-induced vascular smooth muscle cell phenotypic transition and proliferation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2015 31 6 775 8 26062420
Zhou W, Liu W, Liao H, Cao Z, Xie H, Zhang S, et al. [Testosterone suppresses oxidized low-density lipoprotein-induced vascular smooth muscle cell phenotypic transition and proliferation]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015;31(6):775–8.26062420
102. Pang H Xiao L Lu Z Chen H Shang Z Jiang N Targeting androgen receptor in macrophages inhibits phosphate-induced vascular smooth muscle cell calcification by decreasing IL-6 expression Vascul Pharmacol 2020 130 106681 10.1016/j.vph.2020.106681 32387336
Pang H, Xiao L, Lu Z, Chen H, Shang Z, Jiang N, et al. Targeting androgen receptor in macrophages inhibits phosphate-induced vascular smooth muscle cell calcification by decreasing IL-6 expression. Vascul Pharmacol. 2020;130:106681. 10.1016/j.vph.2020.106681.32387336 10.1016/j.vph.2020.106681
103. Zhu D Hadoke PW Wu J Vesey AT Lerman DA Dweck MR Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification Sci Rep 2016 6 1 24807 10.1038/srep24807 27095121
Zhu D, Hadoke PW, Wu J, Vesey AT, Lerman DA, Dweck MR, et al. Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. Sci Rep. 2016;6(1):24807. 10.1038/srep24807.27095121 10.1038/srep24807
104. Pugliese G Iacobini C Blasetti Fantauzzi C Menini S The dark and bright side of atherosclerotic calcification Atherosclerosis 2015 238 2 220 30 10.1016/j.atherosclerosis.2014.12.011 25528431
Pugliese G, Iacobini C, Blasetti Fantauzzi C, Menini S. The dark and bright side of atherosclerotic calcification. Atherosclerosis. 2015;238(2):220–30. 10.1016/j.atherosclerosis.2014.12.011.25528431 10.1016/j.atherosclerosis.2014.12.011
105. Cutini PH Massheimer VL In vitro effects of progesterone and the synthetic progestin medroxyprogesterone acetate on vascular remodeling Mol Cell Endocrinol 2019 498 110543 10.1016/j.mce.2019.110543 31421164
Cutini PH, Massheimer VL. In vitro effects of progesterone and the synthetic progestin medroxyprogesterone acetate on vascular remodeling. Mol Cell Endocrinol. 2019;498:110543. 10.1016/j.mce.2019.110543.31421164 10.1016/j.mce.2019.110543
106. Quinkler M Kaur K Hewison M Stewart PM Cooper MS Progesterone is extensively metabolized in osteoblasts: implications for progesterone action on bone Horm Metab Res 2008 40 10 679 84 10.1055/s-2008-1078718 18537080
Quinkler M, Kaur K, Hewison M, Stewart PM, Cooper MS. Progesterone is extensively metabolized in osteoblasts: implications for progesterone action on bone. Horm Metab Res. 2008;40(10):679–84. 10.1055/s-2008-1078718.18537080 10.1055/s-2008-1078718
107. Kolodgie FD Jacob A Wilson PS Carlson GC Farb A Verma A Estradiol attenuates directed migration of vascular smooth muscle cells in vitro Am J Pathol 1996 148 3 969 76 8774151
Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, et al. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol. 1996;148(3):969–76.8774151
108. Bhalla RC Toth KF Bhatty RA Thompson LP Sharma RV Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells Am J Physiol 1997 272 4 Pt 2 H1996 2003 10.1152/ajpheart.1997.272.4.H1996 9139988
Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV. Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol. 1997;272(4 Pt 2):H1996–2003. 10.1152/ajpheart.1997.272.4.H1996.9139988 10.1152/ajpheart.1997.272.4.H1996
109. Greig FH Nixon GF Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states Pharmacol Ther 2014 143 3 265 74 10.1016/j.pharmthera.2014.03.006 24657708
Greig FH, Nixon GF. Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states. Pharmacol Ther. 2014;143(3):265–74. 10.1016/j.pharmthera.2014.03.006.24657708 10.1016/j.pharmthera.2014.03.006
110. Meloche S Pouyssegur J The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition Oncogene 2007 26 22 3227 39 10.1038/sj.onc.1210414 17496918
Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26(22):3227–39. 10.1038/sj.onc.1210414.17496918 10.1038/sj.onc.1210414
111. Huang X Jin Y Zhou D Xu G Huang J Shen L IQGAP1 modulates the proliferation and migration of vascular smooth muscle cells in response to estrogen Int J Mol Med 2015 35 5 1460 6 10.3892/ijmm.2015.2134 25777140
Huang X, Jin Y, Zhou D, Xu G, Huang J, Shen L. IQGAP1 modulates the proliferation and migration of vascular smooth muscle cells in response to estrogen. Int J Mol Med. 2015;35(5):1460–6. 10.3892/ijmm.2015.2134.25777140 10.3892/ijmm.2015.2134
112. Ding Q Gros R Limbird LE Chorazyczewski J Feldman RD Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30 Am J Physiol Cell Physiol 2009 297 5 C1178 87 10.1152/ajpcell.00185.2009 19741198
Ding Q, Gros R, Limbird LE, Chorazyczewski J, Feldman RD. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol Cell Physiol. 2009;297(5):C1178–87. 10.1152/ajpcell.00185.2009.19741198 10.1152/ajpcell.00185.2009
113. Feldman RD Gros R Rapid vascular effects of steroids - a question of balance? Can J Cardiol 2010 26 Suppl A A22 6 10.1016/s0828-282x(10)71057-6
Feldman RD, Gros R. Rapid vascular effects of steroids - a question of balance? Can J Cardiol. 2010;26(Suppl A):A22–6. 10.1016/s0828-282x(10)71057-6.10.1016/s0828-282x(10)71057-6
114. Schachter M Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers Int J Cardiol 1997 62 Suppl 2 S85 90 10.1016/s0167-5273(97)00245-3 9488199
Schachter M. Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers. Int J Cardiol. 1997;62(Suppl 2):S85–90. 10.1016/s0167-5273(97)00245-3.9488199 10.1016/s0167-5273(97)00245-3
115. Ortmann J Veit M Zingg S Di Santo S Traupe T Yang Z Estrogen receptor-alpha but not -beta or GPER inhibits high glucose-induced human VSMC proliferation: potential role of ROS and ERK J Clin Endocrinol Metab 2011 96 1 220 8 10.1210/jc.2010-0943 20962025
Ortmann J, Veit M, Zingg S, Di Santo S, Traupe T, Yang Z, et al. Estrogen receptor-alpha but not -beta or GPER inhibits high glucose-induced human VSMC proliferation: potential role of ROS and ERK. J Clin Endocrinol Metab. 2011;96(1):220–8. 10.1210/jc.2010-0943.20962025 10.1210/jc.2010-0943
116. Cheng B Song J Zou Y Wang Q Lei Y Zhu C Responses of vascular smooth muscle cells to estrogen are dependent on balance between ERK and p38 MAPK pathway activities Int J Cardiol 2009 134 3 356 65 10.1016/j.ijcard.2008.02.017 18584900
Cheng B, Song J, Zou Y, Wang Q, Lei Y, Zhu C, et al. Responses of vascular smooth muscle cells to estrogen are dependent on balance between ERK and p38 MAPK pathway activities. Int J Cardiol. 2009;134(3):356–65. 10.1016/j.ijcard.2008.02.017.18584900 10.1016/j.ijcard.2008.02.017
117. Lees JA Saito M Vidal M Valentine M Look T Harlow E The retinoblastoma protein binds to a family of E2F transcription factors Mol Cell Biol 1993 13 12 7813 25 10.1128/mcb.13.12.7813-7825.1993 8246996
Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol. 1993;13(12):7813–25. 10.1128/mcb.13.12.7813-7825.1993.8246996 10.1128/mcb.13.12.7813-7825.1993
118. Takahashi K Ohmichi M Yoshida M Hisamoto K Mabuchi S Arimoto-Ishida E Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells J Endocrinol 2003 178 2 319 29 10.1677/joe.0.1780319 12904179
Takahashi K, Ohmichi M, Yoshida M, Hisamoto K, Mabuchi S, Arimoto-Ishida E, et al. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol. 2003;178(2):319–29. 10.1677/joe.0.1780319.12904179 10.1677/joe.0.1780319
119. Li Q Zhu L Zhang L Chen H Zhu Y Du Y Inhibition of estrogen related receptor alpha attenuates vascular smooth muscle cell proliferation and migration by regulating RhoA/p27(Kip1) and beta-Catenin/Wnt4 signaling pathway Eur J Pharmacol 2017 799 188 95 10.1016/j.ejphar.2017.02.020 28213288
Li Q, Zhu L, Zhang L, Chen H, Zhu Y, Du Y, et al. Inhibition of estrogen related receptor alpha attenuates vascular smooth muscle cell proliferation and migration by regulating RhoA/p27(Kip1) and beta-Catenin/Wnt4 signaling pathway. Eur J Pharmacol. 2017;799:188–95. 10.1016/j.ejphar.2017.02.020.28213288 10.1016/j.ejphar.2017.02.020
120. Barchiesi F Jackson EK Fingerle J Gillespie DG Odermatt B Dubey RK 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle Circ Res 2006 99 3 266 74 10.1161/01.RES.0000233318.85181.2e 16794187
Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res. 2006;99(3):266–74. 10.1161/01.RES.0000233318.85181.2e.16794187 10.1161/01.RES.0000233318.85181.2e
121. Chi C Li DJ Jiang YJ Tong J Fu H Wu YH Vascular smooth muscle cell senescence and age-related diseases: state of the art Biochim Biophys Acta Mol Basis Dis 2019 1865 7 1810 21 10.1016/j.bbadis.2018.08.015 31109451
Chi C, Li DJ, Jiang YJ, Tong J, Fu H, Wu YH, et al. Vascular smooth muscle cell senescence and age-related diseases: state of the art. Biochim Biophys Acta Mol Basis Dis. 2019;1865(7):1810–21. 10.1016/j.bbadis.2018.08.015.31109451 10.1016/j.bbadis.2018.08.015
122. Linton MF Moslehi JJ Babaev VR Akt signaling in macrophage polarization, survival, and atherosclerosis Int J Mol Sci 2019 20 11 2703 10.3390/ijms20112703 31159424
Linton MF, Moslehi JJ, Babaev VR. Akt signaling in macrophage polarization, survival, and atherosclerosis. Int J Mol Sci. 2019;20(11):2703. 10.3390/ijms20112703.31159424 10.3390/ijms20112703
123. Bonnet S Paulin R Sutendra G Dromparis P Roy M Watson KO Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-beta/NFAT axis Circulation 2009 120 13 1231 40 10.1161/CIRCULATIONAHA.109.848911 19752325
Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, et al. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-beta/NFAT axis. Circulation. 2009;120(13):1231–40. 10.1161/CIRCULATIONAHA.109.848911.19752325 10.1161/CIRCULATIONAHA.109.848911
124. Chang C Wang D Xi L Guo X Wang G Yu G The orphan GPR50 receptor interacting with TbetaRI induces G1/S-phase cell cycle arrest via Smad3-p27/p21 in BRL-3A cells Biochem Pharmacol 2022 202 115117 10.1016/j.bcp.2022.115117 35671788
Chang C, Wang D, Xi L, Guo X, Wang G, Yu G. The orphan GPR50 receptor interacting with TbetaRI induces G1/S-phase cell cycle arrest via Smad3-p27/p21 in BRL-3A cells. Biochem Pharmacol. 2022;202:115117. 10.1016/j.bcp.2022.115117.35671788 10.1016/j.bcp.2022.115117
125. Lee CH Su SC Chiang CF Chien CY Hsu CC Yu TY Estrogen modulates vascular smooth muscle cell function through downregulation of SIRT1 Oncotarget 2017 8 66 110039 51 10.18632/oncotarget.22546 29299128
Lee CH, Su SC, Chiang CF, Chien CY, Hsu CC, Yu TY, et al. Estrogen modulates vascular smooth muscle cell function through downregulation of SIRT1. Oncotarget. 2017;8(66):110039–51. 10.18632/oncotarget.22546.29299128 10.18632/oncotarget.22546
126. Ueda K Lu Q Baur W Aronovitz MJ Karas RH Rapid estrogen receptor signaling mediates estrogen-induced inhibition of vascular smooth muscle cell proliferation Arterioscler Thromb Vasc Biol 2013 33 8 1837 43 10.1161/ATVBAHA.112.300752 23744991
Ueda K, Lu Q, Baur W, Aronovitz MJ, Karas RH. Rapid estrogen receptor signaling mediates estrogen-induced inhibition of vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol. 2013;33(8):1837–43. 10.1161/ATVBAHA.112.300752.23744991 10.1161/ATVBAHA.112.300752
127. Son BK Akishita M Iijima K Ogawa S Maemura K Yu J Androgen receptor-dependent transactivation of growth arrest-specific gene 6 mediates inhibitory effects of testosterone on vascular calcification J Biol Chem 2010 285 10 7537 44 10.1074/jbc.M109.055087 20048160
Son BK, Akishita M, Iijima K, Ogawa S, Maemura K, Yu J, et al. Androgen receptor-dependent transactivation of growth arrest-specific gene 6 mediates inhibitory effects of testosterone on vascular calcification. J Biol Chem. 2010;285(10):7537–44. 10.1074/jbc.M109.055087.20048160 10.1074/jbc.M109.055087
128. Nanao-Hamai M, Son BK, Komuro A, Asari Y, Hashizume T, Takayama K et al. Ginsenoside Rb1 inhibits vascular calcification as a selective androgen receptor modulator. European Journal of Pharmacology. 2019;859:172546. doi: ARTN 172546. 10.1016/j.ejphar.2019.172546.
129. Heo Y Jeon H Namkung W PAR4-Mediated PI3K/Akt and RhoA/ROCK signaling pathways are essential for Thrombin-Induced morphological changes in MEG-01 cells Int J Mol Sci 2022 23 2 776 10.3390/ijms23020776 35054966
Heo Y, Jeon H, Namkung W. PAR4-Mediated PI3K/Akt and RhoA/ROCK signaling pathways are essential for Thrombin-Induced morphological changes in MEG-01 cells. Int J Mol Sci. 2022;23(2):776. 10.3390/ijms23020776.35054966 10.3390/ijms23020776
130. Gallou-Kabani C Vige A Gross MS Junien C Nutri-epigenomics: lifelong remodelling of our epigenomes by nutritional and metabolic factors and beyond Clin Chem Lab Med 2007 45 3 321 7 10.1515/CCLM.2007.081 17378726
Gallou-Kabani C, Vige A, Gross MS, Junien C. Nutri-epigenomics: lifelong remodelling of our epigenomes by nutritional and metabolic factors and beyond. Clin Chem Lab Med. 2007;45(3):321–7. 10.1515/CCLM.2007.081.17378726 10.1515/CCLM.2007.081
131. Kuhlmann JD Rasch J Wimberger P Kasimir-Bauer S microRNA and the pathogenesis of ovarian cancer–a new horizon for molecular diagnostics and treatment? Clin Chem Lab Med 2012 50 4 601 15 10.1515/cclm-2011-0847 22505556
Kuhlmann JD, Rasch J, Wimberger P, Kasimir-Bauer S. microRNA and the pathogenesis of ovarian cancer–a new horizon for molecular diagnostics and treatment? Clin Chem Lab Med. 2012;50(4):601–15. 10.1515/cclm-2011-0847.22505556 10.1515/cclm-2011-0847
132. Lin HF Hsi E Liao YC Chhor B Hung J Juo SH Demethylation of circulating estrogen receptor alpha gene in cerebral ischemic stroke PLoS ONE 2015 10 9 e0139608 10.1371/journal.pone.0139608 26422690
Lin HF, Hsi E, Liao YC, Chhor B, Hung J, Juo SH, et al. Demethylation of circulating estrogen receptor alpha gene in cerebral ischemic stroke. PLoS ONE. 2015;10(9):e0139608. 10.1371/journal.pone.0139608.26422690 10.1371/journal.pone.0139608
133. Wong LM Phoon LQ Wei LK Epigenetics modifications in large-artery atherosclerosis: a systematic review J Stroke Cerebrovasc Dis 2021 30 12 106033 10.1016/j.jstrokecerebrovasdis.2021.106033 34598837
Wong LM, Phoon LQ, Wei LK. Epigenetics modifications in large-artery atherosclerosis: a systematic review. J Stroke Cerebrovasc Dis. 2021;30(12):106033. 10.1016/j.jstrokecerebrovasdis.2021.106033.34598837 10.1016/j.jstrokecerebrovasdis.2021.106033
134. Molvarec A Szeplaki G Kovacs M Szeplaki Z Fazakas A Prohaszka Z Estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms in ischemic stroke in a Hungarian population Clin Chim Acta 2007 382 1–2 100 5 10.1016/j.cca.2007.04.003 17493601
Molvarec A, Szeplaki G, Kovacs M, Szeplaki Z, Fazakas A, Prohaszka Z, et al. Estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms in ischemic stroke in a Hungarian population. Clin Chim Acta. 2007;382(1–2):100–5. 10.1016/j.cca.2007.04.003.17493601 10.1016/j.cca.2007.04.003
135. Min J Weitian Z Peng C Yan P Bo Z Yan W Correlation between insulin-induced estrogen receptor methylation and atherosclerosis Cardiovasc Diabetol 2016 15 1 156 10.1186/s12933-016-0471-9 27832775
Min J, Weitian Z, Peng C, Yan P, Bo Z, Yan W, et al. Correlation between insulin-induced estrogen receptor methylation and atherosclerosis. Cardiovasc Diabetol. 2016;15(1):156. 10.1186/s12933-016-0471-9.27832775 10.1186/s12933-016-0471-9
136. Taheri M Shoorei H Dinger ME Ghafouri-Fard S Perspectives on the role of non-coding RNAs in the regulation of expression and function of the estrogen receptor Cancers (Basel) 2020 12 8 2162 10.3390/cancers12082162 32759784
Taheri M, Shoorei H, Dinger ME, Ghafouri-Fard S. Perspectives on the role of non-coding RNAs in the regulation of expression and function of the estrogen receptor. Cancers (Basel). 2020;12(8):2162. 10.3390/cancers12082162.32759784 10.3390/cancers12082162
137. Horton AC Wilkinson MM Kilanowski-Doroh I Ogola BO Lindsey SH Dihydrotestosterone induces arterial stiffening in female mice Res Sq 2023 15 1 9 10.21203/rs.3.rs-2522089/v1
Horton AC, Wilkinson MM, Kilanowski-Doroh I, Ogola BO, Lindsey SH. Dihydrotestosterone induces arterial stiffening in female mice. Res Sq. 2023;15(1):9. 10.21203/rs.3.rs-2522089/v1.10.21203/rs.3.rs-2522089/v1
138. Harvey A Montezano AC Touyz RM Vascular biology of ageing-implications in hypertension J Mol Cell Cardiol 2015 83 112 21 10.1016/j.yjmcc.2015.04.011 25896391
Harvey A, Montezano AC, Touyz RM. Vascular biology of ageing-implications in hypertension. J Mol Cell Cardiol. 2015;83:112–21. 10.1016/j.yjmcc.2015.04.011.25896391 10.1016/j.yjmcc.2015.04.011
139. Sasaki Y Ikeda Y Uchikado Y Akasaki Y Sadoshima J Ohishi M Estrogen plays a crucial role in Rab9-Dependent mitochondrial autophagy, delaying arterial senescence J Am Heart Assoc 2021 10 7 e019310 10.1161/JAHA.120.019310 33719502
Sasaki Y, Ikeda Y, Uchikado Y, Akasaki Y, Sadoshima J, Ohishi M. Estrogen plays a crucial role in Rab9-Dependent mitochondrial autophagy, delaying arterial senescence. J Am Heart Assoc. 2021;10(7):e019310. 10.1161/JAHA.120.019310.33719502 10.1161/JAHA.120.019310
140. Arnal JF Fontaine C Billon-Gales A Favre J Laurell H Lenfant F Estrogen receptors and endothelium Arterioscler Thromb Vasc Biol 2010 30 8 1506 12 10.1161/ATVBAHA.109.191221 20631350
Arnal JF, Fontaine C, Billon-Gales A, Favre J, Laurell H, Lenfant F, et al. Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol. 2010;30(8):1506–12. 10.1161/ATVBAHA.109.191221.20631350 10.1161/ATVBAHA.109.191221
141. Smirnova NF Fontaine C Buscato M Lupieri A Vinel A Valera MC The activation Function-1 of estrogen receptor alpha prevents arterial Neointima Development through a direct effect on smooth muscle cells Circul Res 2015 117 9 770 8 10.1161/Circresaha.115.306416
Smirnova NF, Fontaine C, Buscato M, Lupieri A, Vinel A, Valera MC, et al. The activation Function-1 of estrogen receptor alpha prevents arterial Neointima Development through a direct effect on smooth muscle cells. Circul Res. 2015;117(9):770–8. 10.1161/Circresaha.115.306416.10.1161/Circresaha.115.306416
142. Novensa L Novella S Medina P Segarra G Castillo N Heras M Aging negatively affects estrogens-mediated effects on nitric oxide bioavailability by shifting ERalpha/ERbeta balance in female mice PLoS ONE 2011 6 9 e25335 10.1371/journal.pone.0025335 21966501
Novensa L, Novella S, Medina P, Segarra G, Castillo N, Heras M, et al. Aging negatively affects estrogens-mediated effects on nitric oxide bioavailability by shifting ERalpha/ERbeta balance in female mice. PLoS ONE. 2011;6(9):e25335. 10.1371/journal.pone.0025335.21966501 10.1371/journal.pone.0025335
143. Bowling MR Xing D Kapadia A Chen YF Szalai AJ Oparil S Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors Arterioscler Thromb Vasc Biol 2014 34 7 1477 85 10.1161/ATVBAHA.114.303629 24876352
Bowling MR, Xing D, Kapadia A, Chen YF, Szalai AJ, Oparil S, et al. Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors. Arterioscler Thromb Vasc Biol. 2014;34(7):1477–85. 10.1161/ATVBAHA.114.303629.24876352 10.1161/ATVBAHA.114.303629
144. Chen YQ Zhao J Jin CW Li YH Tang MX Wang ZH Testosterone delays vascular smooth muscle cell senescence and inhibits collagen synthesis via the Gas6/Axl signaling pathway Age (Dordr) 2016 38 3 60 10.1007/s11357-016-9910-5 27206970
Chen YQ, Zhao J, Jin CW, Li YH, Tang MX, Wang ZH, et al. Testosterone delays vascular smooth muscle cell senescence and inhibits collagen synthesis via the Gas6/Axl signaling pathway. Age (Dordr). 2016;38(3):60. 10.1007/s11357-016-9910-5.27206970 10.1007/s11357-016-9910-5
145. Yildiz O Seyrek M Gul H Un I Yildirim V Ozal E Testosterone relaxes human internal mammary artery in vitro J Cardiovasc Pharmacol 2005 45 6 580 5 10.1097/01.fjc.0000161400.06704.1e 15897786
Yildiz O, Seyrek M, Gul H, Un I, Yildirim V, Ozal E, et al. Testosterone relaxes human internal mammary artery in vitro. J Cardiovasc Pharmacol. 2005;45(6):580–5. 10.1097/01.fjc.0000161400.06704.1e.15897786 10.1097/01.fjc.0000161400.06704.1e
146. Zhou P Fu L Pan Z Ma D Zhang Y Qu F Testosterone deprivation by castration impairs expression of voltage-dependent potassium channels in rat aorta Eur J Pharmacol 2008 593 1–3 87 91 10.1016/j.ejphar.2008.07.014 18662681
Zhou P, Fu L, Pan Z, Ma D, Zhang Y, Qu F, et al. Testosterone deprivation by castration impairs expression of voltage-dependent potassium channels in rat aorta. Eur J Pharmacol. 2008;593(1–3):87–91. 10.1016/j.ejphar.2008.07.014.18662681 10.1016/j.ejphar.2008.07.014
147. Chignalia AZ Schuldt EZ Camargo LL Montezano AC Callera GE Laurindo FR Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src-dependent pathways Hypertension 2012 59 6 1263 71 10.1161/HYPERTENSIONAHA.111.180620 22566500
Chignalia AZ, Schuldt EZ, Camargo LL, Montezano AC, Callera GE, Laurindo FR, et al. Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src-dependent pathways. Hypertension. 2012;59(6):1263–71. 10.1161/HYPERTENSIONAHA.111.180620.22566500 10.1161/HYPERTENSIONAHA.111.180620
148. English KM Jones RD Jones TH Morice AH Channer KS Aging reduces the responsiveness of coronary arteries from male Wistar rats to the vasodilatory action of testosterone Clin Sci (Lond) 2000 99 1 77 82 10.1042/cs0990077 10887060
English KM, Jones RD, Jones TH, Morice AH, Channer KS. Aging reduces the responsiveness of coronary arteries from male Wistar rats to the vasodilatory action of testosterone. Clin Sci (Lond). 2000;99(1):77–82.10887060 10.1042/cs0990077
149. Lopes RA Neves KB Carneiro FS Tostes RC Testosterone and vascular function in aging Front Physiol 2012 3 89 10.3389/fphys.2012.00089 22514541
Lopes RA, Neves KB, Carneiro FS, Tostes RC. Testosterone and vascular function in aging. Front Physiol. 2012;3:89. 10.3389/fphys.2012.00089.22514541 10.3389/fphys.2012.00089
150. Bostrom KI Where do we stand on vascular calcification? Vascul Pharmacol 2016 84 8 14 10.1016/j.vph.2016.05.014 27260939
Bostrom KI. Where do we stand on vascular calcification? Vascul Pharmacol. 2016;84:8–14. 10.1016/j.vph.2016.05.014.27260939 10.1016/j.vph.2016.05.014
151. Steitz SA Speer MY Curinga G Yang HY Haynes P Aebersold R Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers Circ Res 2001 89 12 1147 54 10.1161/hh2401.101070 11739279
Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89(12):1147–54. 10.1161/hh2401.101070.11739279 10.1161/hh2401.101070
152. Speer MY Yang HY Brabb T Leaf E Look A Lin WL Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries Circ Res 2009 104 6 733 41 10.1161/CIRCRESAHA.108.183053 19197075
Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104(6):733–41. 10.1161/CIRCRESAHA.108.183053.19197075 10.1161/CIRCRESAHA.108.183053
153. Wu X Zhao Q Chen Z Geng YJ Zhang W Zhou Q Estrogen inhibits vascular calcification in rats via hypoxia-induced factor-1alpha signaling Vascular 2020 28 4 465 74 10.1177/1708538120904297 32089109
Wu X, Zhao Q, Chen Z, Geng YJ, Zhang W, Zhou Q, et al. Estrogen inhibits vascular calcification in rats via hypoxia-induced factor-1alpha signaling. Vascular. 2020;28(4):465–74. 10.1177/1708538120904297.32089109 10.1177/1708538120904297
154. Tharp DL Ivey JR Shaw RL Bowles DK Ovariectomy increases L-type ca(2+) channel activity in porcine coronary smooth muscle Menopause 2014 21 6 661 8 10.1097/GME.0000000000000087 24848355
Tharp DL, Ivey JR, Shaw RL, Bowles DK. Ovariectomy increases L-type ca(2+) channel activity in porcine coronary smooth muscle. Menopause. 2014;21(6):661–8. 10.1097/GME.0000000000000087.24848355 10.1097/GME.0000000000000087
155. Pang Y Thomas P Role of mPRalpha (PAQR7) in progesterone-induced Ca2 + decrease in human vascular smooth muscle cells J Mol Endocrinol 2019 63 3 199 213 10.1530/JME-19-0019 31416049
Pang Y, Thomas P. Role of mPRalpha (PAQR7) in progesterone-induced Ca2 + decrease in human vascular smooth muscle cells. J Mol Endocrinol. 2019;63(3):199–213. 10.1530/JME-19-0019.31416049 10.1530/JME-19-0019
156. Hu Z Ma R Gong J Investigation of testosterone-mediated non-transcriptional inhibition of ca(2+) in vascular smooth muscle cells Biomed Rep 2016 4 2 197 202 10.3892/br.2015.557 26893838
Hu Z, Ma R, Gong J. Investigation of testosterone-mediated non-transcriptional inhibition of ca(2+) in vascular smooth muscle cells. Biomed Rep. 2016;4(2):197–202. 10.3892/br.2015.557.26893838 10.3892/br.2015.557
157. Mendelsohn ME Karas RH The protective effects of estrogen on the cardiovascular system N Engl J Med 1999 340 23 1801 11 10.1056/NEJM199906103402306 10362825
Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–11. 10.1056/NEJM199906103402306.10362825 10.1056/NEJM199906103402306
158. Barton M Cholesterol and atherosclerosis: modulation by oestrogen Curr Opin Lipidol 2013 24 3 214 20 10.1097/MOL.0b013e3283613a94 23594711
Barton M. Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol. 2013;24(3):214–20. 10.1097/MOL.0b013e3283613a94.23594711 10.1097/MOL.0b013e3283613a94
159. Rossouw JE Anderson GL Prentice RL LaCroix AZ Kooperberg C Stefanick ML Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s Health Initiative randomized controlled trial JAMA 2002 288 3 321 33 10.1001/jama.288.3.321 12117397
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. 10.1001/jama.288.3.321.12117397 10.1001/jama.288.3.321
160. Bruck B Brehme U Gugel N Hanke S Finking G Lutz C Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits Arterioscler Thromb Vasc Biol 1997 17 10 2192 9 10.1161/01.atv.17.10.2192 9351389
Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1997;17(10):2192–9. 10.1161/01.atv.17.10.2192.9351389 10.1161/01.atv.17.10.2192
161. Njoroge JN Tressel W Biggs ML Matsumoto AM Smith NL Rosenberg E Circulating androgen concentrations and risk of Incident Heart failure in older men: the Cardiovascular Health Study J Am Heart Assoc 2022 11 21 e026953 10.1161/JAHA.122.026953 36285783
Njoroge JN, Tressel W, Biggs ML, Matsumoto AM, Smith NL, Rosenberg E, et al. Circulating androgen concentrations and risk of Incident Heart failure in older men: the Cardiovascular Health Study. J Am Heart Assoc. 2022;11(21):e026953. 10.1161/JAHA.122.026953.36285783 10.1161/JAHA.122.026953
162. Chaikof EL Dalman RL Eskandari MK Jackson BM Lee WA Mansour MA The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm J Vasc Surg 2018 67 1 2 e772 10.1016/j.jvs.2017.10.044 29268916
Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2–e772. 10.1016/j.jvs.2017.10.044.29268916 10.1016/j.jvs.2017.10.044
163. Gravitte A Archibald T Cobble A Kennard B Brown S Liquid chromatography-mass spectrometry applications for quantification of endogenous sex hormones Biomed Chromatogr 2021 35 1 e5036 10.1002/bmc.5036 33226656
Gravitte A, Archibald T, Cobble A, Kennard B, Brown S. Liquid chromatography-mass spectrometry applications for quantification of endogenous sex hormones. Biomed Chromatogr. 2021;35(1):e5036. 10.1002/bmc.5036.33226656 10.1002/bmc.5036
164. Wu XF Zhang J Paskauskas S Xin SJ Duan ZQ The role of estrogen in the formation of experimental abdominal aortic aneurysm Am J Surg 2009 197 1 49 54 10.1016/j.amjsurg.2007.11.022 18585678
Wu XF, Zhang J, Paskauskas S, Xin SJ, Duan ZQ. The role of estrogen in the formation of experimental abdominal aortic aneurysm. Am J Surg. 2009;197(1):49–54. 10.1016/j.amjsurg.2007.11.022.18585678 10.1016/j.amjsurg.2007.11.022
165. Chen S Zhao Y Jin H Qi X He J Huang J TROVE2 strengthens the anti-inflammatory effect via macrophage polarization by estrogen induction in abdominal aortic aneurysm Life Sci 2020 242 117207 10.1016/j.lfs.2019.117207 31863777
Chen S, Zhao Y, Jin H, Qi X, He J, Huang J, et al. TROVE2 strengthens the anti-inflammatory effect via macrophage polarization by estrogen induction in abdominal aortic aneurysm. Life Sci. 2020;242:117207. 10.1016/j.lfs.2019.117207.31863777 10.1016/j.lfs.2019.117207
166. Gavish L Gilon D Beeri R Zuckerman A Nachman D Gertz SD Photobiomodulation and estrogen stabilize mitochondrial membrane potential in angiotensin-II challenged porcine aortic smooth muscle cells J Biophotonics 2021 14 1 e202000329 10.1002/jbio.202000329 32888351
Gavish L, Gilon D, Beeri R, Zuckerman A, Nachman D, Gertz SD. Photobiomodulation and estrogen stabilize mitochondrial membrane potential in angiotensin-II challenged porcine aortic smooth muscle cells. J Biophotonics. 2021;14(1):e202000329. 10.1002/jbio.202000329.32888351 10.1002/jbio.202000329
167. Martin-McNulty B Tham DM da Cunha V Ho JJ Wilson DW Rutledge JC 17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 2003 23 9 1627 32 10.1161/01.ATV.0000085842.20866.6A 12855485
Martin-McNulty B, Tham DM, da Cunha V, Ho JJ, Wilson DW, Rutledge JC, et al. 17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23(9):1627–32. 10.1161/01.ATV.0000085842.20866.6A.12855485 10.1161/01.ATV.0000085842.20866.6A
168. Woodrum DT Ford JW Cho BS Hannawa KK Stanley JC Henke PK Differential effect of 17-beta-estradiol on smooth muscle cell and aortic explant MMP2 J Surg Res 2009 155 1 48 53 10.1016/j.jss.2008.07.003 19041098
Woodrum DT, Ford JW, Cho BS, Hannawa KK, Stanley JC, Henke PK, et al. Differential effect of 17-beta-estradiol on smooth muscle cell and aortic explant MMP2. J Surg Res. 2009;155(1):48–53. 10.1016/j.jss.2008.07.003.19041098 10.1016/j.jss.2008.07.003
169. Petsophonsakul P Furmanik M Forsythe R Dweck M Schurink GW Natour E Role of vascular smooth muscle cell phenotypic switching and calcification in aortic aneurysm formation Arterioscler Thromb Vasc Biol 2019 39 7 1351 68 10.1161/ATVBAHA.119.312787 31144989
Petsophonsakul P, Furmanik M, Forsythe R, Dweck M, Schurink GW, Natour E, et al. Role of vascular smooth muscle cell phenotypic switching and calcification in aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2019;39(7):1351–68. 10.1161/ATVBAHA.119.312787.31144989 10.1161/ATVBAHA.119.312787
170. Villard C Swedenborg J Eriksson P Hultgren R Reproductive history in women with abdominal aortic aneurysms J Vasc Surg 2011 54 2 341 5 10.1016/j.jvs.2010.12.069 21620618
Villard C, Swedenborg J, Eriksson P, Hultgren R. Reproductive history in women with abdominal aortic aneurysms. J Vasc Surg. 2011;54(2):341–5. 10.1016/j.jvs.2010.12.069. 5 e1-2.21620618 10.1016/j.jvs.2010.12.069
171. Burger HG Dudley EC Hopper JL Groome N Guthrie JR Green A Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women J Clin Endocrinol Metab 1999 84 11 4025 30 10.1210/jcem.84.11.6158 10566644
Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab. 1999;84(11):4025–30. 10.1210/jcem.84.11.6158.10566644 10.1210/jcem.84.11.6158
172. Hall JE Endocrinology of the menopause Endocrinol Metab Clin North Am 2015 44 3 485 96 10.1016/j.ecl.2015.05.010 26316238
Hall JE. Endocrinology of the menopause. Endocrinol Metab Clin North Am. 2015;44(3):485–96. 10.1016/j.ecl.2015.05.010.26316238 10.1016/j.ecl.2015.05.010
173. Tedjawirja VN Nieuwdorp M Yeung KK Balm R de Waard VA Novel Hypothesis A role for follicle stimulating hormone in abdominal aortic Aneurysm Development in Postmenopausal Women Front Endocrinol (Lausanne) 2021 12 726107 10.3389/fendo.2021.726107 34721292
Tedjawirja VN, Nieuwdorp M, Yeung KK, Balm R, de Waard VA, Novel Hypothesis. A role for follicle stimulating hormone in abdominal aortic Aneurysm Development in Postmenopausal Women. Front Endocrinol (Lausanne). 2021;12:726107. 10.3389/fendo.2021.726107.34721292 10.3389/fendo.2021.726107
174. Henriques T Zhang X Yiannikouris FB Daugherty A Cassis LA Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 2008 28 7 1251 6 10.1161/ATVBAHA.107.160382 18451329
Henriques T, Zhang X, Yiannikouris FB, Daugherty A, Cassis LA. Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28(7):1251–6. 10.1161/ATVBAHA.107.160382.18451329 10.1161/ATVBAHA.107.160382
175. Zhang X Thatcher S Wu C Daugherty A Cassis LA Castration of male mice prevents the progression of established angiotensin II-induced abdominal aortic aneurysms J Vasc Surg 2015 61 3 767 76 10.1016/j.jvs.2013.11.004 24439319
Zhang X, Thatcher S, Wu C, Daugherty A, Cassis LA. Castration of male mice prevents the progression of established angiotensin II-induced abdominal aortic aneurysms. J Vasc Surg. 2015;61(3):767–76. 10.1016/j.jvs.2013.11.004.24439319 10.1016/j.jvs.2013.11.004
176. Mukherjee K Pingili AK Singh P Dhodi AN Dutta SR Gonzalez FJ Testosterone metabolite 6beta-Hydroxytestosterone contributes to Angiotensin II-Induced Abdominal aortic aneurysms in Apoe(-/-) male mice J Am Heart Assoc 2021 10 7 e018536 10.1161/JAHA.120.018536 33719500
Mukherjee K, Pingili AK, Singh P, Dhodi AN, Dutta SR, Gonzalez FJ, et al. Testosterone metabolite 6beta-Hydroxytestosterone contributes to Angiotensin II-Induced Abdominal aortic aneurysms in Apoe(-/-) male mice. J Am Heart Assoc. 2021;10(7):e018536. 10.1161/JAHA.120.018536.33719500 10.1161/JAHA.120.018536
177. Davis JP, Salmon M, Pope NH, Lu G, Su G, Meher A et al. Pharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation. J Vasc Surg. 2016;63(6):1602-12 e2. 10.1016/j.jvs.2015.11.038
178. Rabinovitch M Molecular pathogenesis of pulmonary arterial hypertension J Clin Invest 2008 118 7 2372 9 10.1172/JCI33452 18596905
Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2008;118(7):2372–9. 10.1172/JCI33452.18596905 10.1172/JCI33452
179. Sheikh AQ Lighthouse JK Greif DM Recapitulation of developing artery muscularization in pulmonary hypertension Cell Rep 2014 6 5 809 17 10.1016/j.celrep.2014.01.042 24582963
Sheikh AQ, Lighthouse JK, Greif DM. Recapitulation of developing artery muscularization in pulmonary hypertension. Cell Rep. 2014;6(5):809–17. 10.1016/j.celrep.2014.01.042.24582963 10.1016/j.celrep.2014.01.042
180. Sheikh AQ Misra A Rosas IO Adams RH Greif DM Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension Sci Transl Med 2015 7 308 308ra159 10.1126/scitranslmed.aaa9712 26446956
Sheikh AQ, Misra A, Rosas IO, Adams RH, Greif DM. Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension. Sci Transl Med. 2015;7(308):308ra159. 10.1126/scitranslmed.aaa9712.26446956 10.1126/scitranslmed.aaa9712
181. Sheikh AQ Saddouk FZ Ntokou A Mazurek R Greif DM Cell Autonomous and Non-cell Autonomous Regulation of SMC progenitors in Pulmonary Hypertension Cell Rep 2018 23 4 1152 65 10.1016/j.celrep.2018.03.043 29694892
Sheikh AQ, Saddouk FZ, Ntokou A, Mazurek R, Greif DM. Cell Autonomous and Non-cell Autonomous Regulation of SMC progenitors in Pulmonary Hypertension. Cell Rep. 2018;23(4):1152–65. 10.1016/j.celrep.2018.03.043.29694892 10.1016/j.celrep.2018.03.043
182. Ntokou A Dave JM Kauffman AC Sauler M Ryu C Hwa J Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension JCI Insight 2021 6 6 e139067 10.1172/jci.insight.139067 33591958
Ntokou A, Dave JM, Kauffman AC, Sauler M, Ryu C, Hwa J, et al. Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension. JCI Insight. 2021;6(6):e139067. 10.1172/jci.insight.139067.33591958 10.1172/jci.insight.139067
183. Morris H Denver N Gaw R Labazi H Mair K MacLean MR Sex differences in Pulmonary Hypertension Clin Chest Med 2021 42 1 217 28 10.1016/j.ccm.2020.10.005 33541615
Morris H, Denver N, Gaw R, Labazi H, Mair K, MacLean MR. Sex differences in Pulmonary Hypertension. Clin Chest Med. 2021;42(1):217–28. 10.1016/j.ccm.2020.10.005.33541615 10.1016/j.ccm.2020.10.005
184. Austin ED Hamid R Hemnes AR Loyd JE Blackwell T Yu C BMPR2 expression is suppressed by signaling through the estrogen receptor Biol Sex Differ 2012 3 1 6 10.1186/2042-6410-3-6 22348410
Austin ED, Hamid R, Hemnes AR, Loyd JE, Blackwell T, Yu C, et al. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ. 2012;3(1):6. 10.1186/2042-6410-3-6.22348410 10.1186/2042-6410-3-6
185. Morrell NW Yang X Upton PD Jourdan KB Morgan N Sheares KK Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins Circulation 2001 104 7 790 5 10.1161/hc3201.094152 11502704
Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 2001;104(7):790–5. 10.1161/hc3201.094152.11502704 10.1161/hc3201.094152
186. Yu PB Deng DY Beppu H Hong CC Lai C Hoyng SA Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells J Biol Chem 2008 283 7 3877 88 10.1074/jbc.M706797200 18042551
Yu PB, Deng DY, Beppu H, Hong CC, Lai C, Hoyng SA, et al. Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem. 2008;283(7):3877–88. 10.1074/jbc.M706797200.18042551 10.1074/jbc.M706797200
187. Mair KM Yang XD Long L White K Wallace E Ewart MA Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells Am J Respir Crit Care Med 2015 191 6 693 703 10.1164/rccm.201410-1802OC 25608111
Mair KM, Yang XD, Long L, White K, Wallace E, Ewart MA, et al. Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2015;191(6):693–703. 10.1164/rccm.201410-1802OC.25608111 10.1164/rccm.201410-1802OC
188. Frump AL Albrecht M Yakubov B Breuils-Bonnet S Nadeau V Tremblay E 17beta-Estradiol and estrogen receptor alpha protect right ventricular function in pulmonary hypertension via BMPR2 and apelin J Clin Invest 2021 131 6 e129433 10.1172/JCI129433 33497359
Frump AL, Albrecht M, Yakubov B, Breuils-Bonnet S, Nadeau V, Tremblay E, et al. 17beta-Estradiol and estrogen receptor alpha protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. J Clin Invest. 2021;131(6):e129433. 10.1172/JCI129433.33497359 10.1172/JCI129433
189. Docherty CK, Harvey KY, Mair KM, Griffin S, Denver N, MacLean MR. The role of sex in the pathophysiology of Pulmonary Hypertension. Sex-specific analysis of Cardiovascular function. Adv Exp Med Biol, 2018. pp. 511–28.
190. Sun Y Sangam S Guo Q Wang J Tang H Black SM Sex differences, Estrogen Metabolism and Signaling in the development of pulmonary arterial hypertension Front Cardiovasc Med 2021 8 719058 10.3389/fcvm.2021.719058 34568460
Sun Y, Sangam S, Guo Q, Wang J, Tang H, Black SM, et al. Sex differences, Estrogen Metabolism and Signaling in the development of pulmonary arterial hypertension. Front Cardiovasc Med. 2021;8:719058. 10.3389/fcvm.2021.719058.34568460 10.3389/fcvm.2021.719058
191. Fessel JP Chen X Frump A Gladson S Blackwell T Kang C Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension Pulm Circ 2013 3 3 564 77 10.1086/674312 24618541
Fessel JP, Chen X, Frump A, Gladson S, Blackwell T, Kang C, et al. Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension. Pulm Circ. 2013;3(3):564–77. 10.1086/674312.24618541 10.1086/674312
192. Austin ED Cogan JD West JD Hedges LK Hamid R Dawson EP Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females Eur Respir J 2009 34 5 1093 9 10.1183/09031936.00010409 19357154
Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J. 2009;34(5):1093–9. 10.1183/09031936.00010409.19357154 10.1183/09031936.00010409
193. White K Johansen AK Nilsen M Ciuclan L Wallace E Paton L Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension Circulation 2012 126 9 1087 98 10.1161/CIRCULATIONAHA.111.062927 22859684
White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, et al. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126(9):1087–98. 10.1161/CIRCULATIONAHA.111.062927.22859684 10.1161/CIRCULATIONAHA.111.062927
194. Hood KY Montezano AC Harvey AP Nilsen M MacLean MR Touyz RM Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Mediated Redox Signaling and vascular remodeling by 16alpha-Hydroxyestrone in human pulmonary artery cells: implications in pulmonary arterial hypertension Hypertension 2016 68 3 796 808 10.1161/HYPERTENSIONAHA.116.07668 27402919
Hood KY, Montezano AC, Harvey AP, Nilsen M, MacLean MR, Touyz RM. Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Mediated Redox Signaling and vascular remodeling by 16alpha-Hydroxyestrone in human pulmonary artery cells: implications in pulmonary arterial hypertension. Hypertension. 2016;68(3):796–808. 10.1161/HYPERTENSIONAHA.116.07668.27402919 10.1161/HYPERTENSIONAHA.116.07668
195. Ogola B Zhang Y Iyer L Thekkumkara T 2-Methoxyestradiol causes matrix metalloproteinase 9-mediated transactivation of epidermal growth factor receptor and angiotensin type 1 receptor downregulation in rat aortic smooth muscle cells Am J Physiol Cell Physiol 2018 314 5 C554 68 10.1152/ajpcell.00152.2017 29365274
Ogola B, Zhang Y, Iyer L, Thekkumkara T. 2-Methoxyestradiol causes matrix metalloproteinase 9-mediated transactivation of epidermal growth factor receptor and angiotensin type 1 receptor downregulation in rat aortic smooth muscle cells. Am J Physiol Cell Physiol. 2018;314(5):C554–68. 10.1152/ajpcell.00152.2017.29365274 10.1152/ajpcell.00152.2017
196. Koganti S Snyder R Gumaste U Karamyan VT Thekkumkara T 2-Methoxyestradiol binding of GPR30 down-regulates angiotensin AT receptor Eur J Pharmacol 2014 723 131 40 10.1016/j.ejphar.2013.10.064 24262995
Koganti S, Snyder R, Gumaste U, Karamyan VT, Thekkumkara T. 2-Methoxyestradiol binding of GPR30 down-regulates angiotensin AT receptor. Eur J Pharmacol. 2014;723:131–40. 10.1016/j.ejphar.2013.10.064.24262995 10.1016/j.ejphar.2013.10.064
197. de la Dumas E Savineau JP Bonnet S Dehydroepiandrosterone A new treatment for vascular remodeling diseases including pulmonary arterial hypertension Pharmacol Ther 2010 126 2 186 99 10.1016/j.pharmthera.2010.02.003 20206649
de la Dumas E, Savineau JP, Bonnet S, Dehydroepiandrosterone. A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther. 2010;126(2):186–99. 10.1016/j.pharmthera.2010.02.003.20206649 10.1016/j.pharmthera.2010.02.003
198. Dessouroux A Akwa Y Baulieu EE DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension J Steroid Biochem Mol Biol 2008 109 1–2 81 9 10.1016/j.jsbmb.2007.12.001 18261897
Dessouroux A, Akwa Y, Baulieu EE. DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension. J Steroid Biochem Mol Biol. 2008;109(1–2):81–9. 10.1016/j.jsbmb.2007.12.001.18261897 10.1016/j.jsbmb.2007.12.001
199. Paulin R Meloche J Jacob MH Bisserier M Courboulin A Bonnet S Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension Am J Physiol Heart Circ Physiol 2011 301 5 H1798 809 10.1152/ajpheart.00654.2011 21890685
Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2011;301(5):H1798–809. 10.1152/ajpheart.00654.2011.21890685 10.1152/ajpheart.00654.2011
200. Riches K Alshanwani AR Warburton P O’Regan DJ Ball SG Wood IC Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with type 2 diabetes drive persistent changes in phenotype and function J Mol Cell Cardiol 2014 74 100 240 50 10.1016/j.yjmcc.2014.05.018 24927876
Riches K, Alshanwani AR, Warburton P, O’Regan DJ, Ball SG, Wood IC, et al. Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with type 2 diabetes drive persistent changes in phenotype and function. J Mol Cell Cardiol. 2014;74(100):240–50. 10.1016/j.yjmcc.2014.05.018.24927876 10.1016/j.yjmcc.2014.05.018
201. Yuan Y Liao L Tulis DA Xu J Steroid receptor coactivator-3 is required for inhibition of neointima formation by estrogen Circulation 2002 105 22 2653 9 10.1161/01.cir.0000018947.95555.65 12045172
Yuan Y, Liao L, Tulis DA, Xu J. Steroid receptor coactivator-3 is required for inhibition of neointima formation by estrogen. Circulation. 2002;105(22):2653–9. 10.1161/01.cir.0000018947.95555.65.12045172 10.1161/01.cir.0000018947.95555.65
202. Zhang C Li H Guo X FOXC2-AS1 regulates phenotypic transition, proliferation and migration of human great saphenous vein smooth muscle cells Biol Res 2019 52 1 59 10.1186/s40659-019-0266-z 31801629
Zhang C, Li H, Guo X. FOXC2-AS1 regulates phenotypic transition, proliferation and migration of human great saphenous vein smooth muscle cells. Biol Res. 2019;52(1):59. 10.1186/s40659-019-0266-z.31801629 10.1186/s40659-019-0266-z
203. Kikuchi S Chen L Xiong K Saito Y Azuma N Tang G Smooth muscle cells of human veins show an increased response to injury at valve sites J Vasc Surg 2018 67 5 1556 e709 10.1016/j.jvs.2017.03.447 28647196
Kikuchi S, Chen L, Xiong K, Saito Y, Azuma N, Tang G, et al. Smooth muscle cells of human veins show an increased response to injury at valve sites. J Vasc Surg. 2018;67(5):1556–e709. 10.1016/j.jvs.2017.03.447.28647196 10.1016/j.jvs.2017.03.447
204. Yin M Tian S Huang X Huang Y Jiang M Role and mechanism of tissue plasminogen activator in venous wall fibrosis remodeling after deep venous thrombosis via the glycogen synthase kinase-3 beta signaling pathway J Surg Res 2013 184 2 1182 95 10.1016/j.jss.2013.03.100 23632004
Yin M, Tian S, Huang X, Huang Y, Jiang M. Role and mechanism of tissue plasminogen activator in venous wall fibrosis remodeling after deep venous thrombosis via the glycogen synthase kinase-3 beta signaling pathway. J Surg Res. 2013;184(2):1182–95. 10.1016/j.jss.2013.03.100.23632004 10.1016/j.jss.2013.03.100
205. Okoth K Chandan JS Marshall T Thangaratinam S Thomas GN Nirantharakumar K Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review BMJ 2020 371 m3502 10.1136/bmj.m3502 33028606
Okoth K, Chandan JS, Marshall T, Thangaratinam S, Thomas GN, Nirantharakumar K, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020;371:m3502. 10.1136/bmj.m3502.33028606 10.1136/bmj.m3502
